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I - Abstract: 
The mitochondrial pathway of apoptosis contributes to cell death and tissue degeneration in a 
variety of human diseases. Targeting the molecular events of this pathway represents a promising 
therapeutic strategy under pathological scenarios, particularly in tissues with limited regenerative 
capability (e.g. brain, heart). Recently, the small molecule ‘TPP-IOA’ was designed to target 
mitochondria and therein inhibit the peroxidase activity of cytochrome c that promotes activation of the 
apoptotic death pathway (Atkinson et al., Nat. Commun. 2011; 2:497). Therefore, TPP-IOA holds 
promise as a potential therapeutic agent in many pathological scenarios of cell loss. However, TPP-
IOA’s target protein and organelle perform critical functions in aerobic ATP production via 
oxidative phosphorylation, and yet little is known about TPP-IOA’s interaction with 
mitochondrial energetics. This is an important consideration for TPP-IOA’s potential future 
therapeutic utility, as avoiding interference to mitochondrial energetics will be essential for many 
target cell types that feature a high rate of oxidative phosphorylation (e.g. neurons, 
cardiomyocytes). Using the purified protein target, isolated organelle target, and live cultured cells, this 
thesis investigated TPP-IOA’s interaction with fundamental components of energetics-related 
mitochondrial biology.  
Assessments with pure cytochrome c revealed that TPP-IOA can inhibit the respiration-
associated reduction activity of cytochrome c, and that this occurred at concentrations marginally 
higher than those required to inhibit the protein’s pro-apoptotic peroxidase activity. In isolated 
rat liver mitochondria, TPP-IOA impaired oxidative phosphorylation via inhibition of both ADP-
phosphorylating-respiration and FCCP-uncoupled respiration, and stimulation of non-
phosphorylating respiration. Critically, TPP-IOA was unable to inhibit pro-apoptotic peroxidase 
activity at concentrations that avoided interference to oxidative phosphorylation, suggesting it may be 
unable to perform its desired pharmacological activity without causing toxicity to mitochondrial 
energetics. In live cultured cells, TPP-IOA caused effects associated with impaired oxidative 
phosphorylation, including a collapsed mitochondrial membrane potential, fragmented mitochondrial 
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network morphology, and apparent loss of mitochondria. Furthermore, TPP-IOA effectively inhibited 
apoptotic death under lethal conditions in cells that preferentially utilized anaerobic glucose metabolism, 
but not in cells manipulated to be heavily reliant on oxidative phosphorylation and thus more sensitive to 
the perturbations to mitochondrial energetics. Altogether, these findings indicate that relative cellular 
dependence on oxidative phosphorylation is a critical factor influencing TPP-IOA’s 
pharmacological efficacy. Furthermore, potential therapeutic applications may be limited to pathologies 
involving predominantly less aerobic tissues/cell types or depressed aerobic metabolism. Additionally, 
these findings have broader implications for mitochondrial medicine based on similar mitochondrial drug 
targeting strategies. 
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Chapter 1.0 - Introduction: 
 
1.1 General Overview: 
This thesis investigates the interaction of the novel mitochondria-targeted anti-apoptotic 
molecule “TPP-IOA” with the mitochondrial protein cytochrome c, and effects on mitochondrial 
energetics, morphology, and turnover. In this chapter, an overview of apoptotic cell death is 
provided, including general descriptions of biochemical and morphological changes, the 
participation of “caspases”, and the role of mitochondria in apoptosis. An overview of cellular 
energy metabolism is given, including roles of oxidative phosphorylation and glycolysis. A brief 
description of the mitochondrial quality control process of mitophagy, along with changes in 
mitochondrial morphology relating to cellular energy metabolism, mitophagy and apoptosis are 
provided.  
There is a growing literature describing the design and use of lipophilic cations in 
targeting mitochondria with pharmacologically-active molecules. Current knowledge regarding 
“TPP-IOA” is reviewed below, including its mechanism of anti-apoptotic action and evidence 
for its pharmacological efficacy. Finally, the existing knowledge of its interaction with 
mitochondrial energetics is covered, as well as the related existing knowledge gaps that are 
important to better understanding the molecule’s anti-apoptotic utility. 
 
1.2 Apoptosis, a form of programmed cell death: 
 The term “apoptosis” comes from a Greek word (prefix “apo”, meaning “separation”, and 
suffix “ptosis”, meaning “to fall”) used to describe the falling off of either leaves from a tree or 
petals from a flower (Kerr et al., 1972; Duque-Parra, 2005). Kerr, Wyllie, & Currie first adopted 
this term for scientific context in 1972 to describe a form of cell death that they and others had 
observed to be largely characterized by seemingly organized and distinct morphological changes 
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(Kerr et al., 1972). This apparent form of cell death was observed in a variety of eukaryotic cells 
and tissues of multi-cellular organisms under different physiological and pathological conditions, 
and was therefore suggested to be an active and inherently programmed or regulated form of cell 
death. After decades of active research, the term is presently still used to describe a main form of 
programmed cell death characterized by distinct morphological features shaped by regulated 
energy-dependent biochemical events.  
Apoptotic cell death is recognized to occur under both physiological and pathological 
states. As a normal physiological process, apoptotic cell death occurs throughout multi-cellular 
organismal development and lifespan as a homeostatic mechanism to maintain cell populations. 
For example, during development excess neurons are produced by the embryonic brain but are 
degraded via apoptosis for proper brain maturation (Roth & D’Sa, 2001). Physiological apoptosis 
is important in opposing mitotic cell death division, and thus ensuring normal cell numbers in 
adult tissues (e.g. Renehan et al., 2001). However, either excessive or insufficient cell death via 
apoptosis can contribute to pathologies associated with various diseases. For example, the loss of 
quiescent cells that typically have little regenerative capacity (e.g. neurons, cardiomyocytes) 
occurs via excessive apoptotic cell death in affected tissues in a variety of disease states (e.g. 
neurodegenerative disorders of the brain or ischemia/reperfusion injury of various highly aerobic 
tissues; Ghavami et al., 2014; Lopez-Neblina et al., 2005). There has been great interest in 
understanding molecular pathways regulating apoptotic cell death in these contexts, as the 
prevention of cell loss and tissue degeneration is a medical goal. 
1.2.1 Morphological and biochemical features of apoptosis: 
Both simple light microscopy and electron microscopy have allowed for a basic 
understanding of the gross morphological and ultrastructural characteristics of apoptosis 
(Häcker, 2000). Generally, the morphological changes occurring during apoptosis include 
(sequentially) cell shrinkage via condensation of the nucleus and cytoplasm, fragmentation of the 
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nucleus, and formation and subsequent budding off of small protuberances of the cell membrane 
to generate many small, spheroid or ovoid plasma membrane-enclosed entities containing 
cytoplasmic contents. These latter structures are known as apoptotic bodies, which become 
phagocytosed and subsequently degraded within phagolysosomes (Kerr et al., 1972).  
Intracellular biochemical and molecular changes underlie the gross morphological 
changes of apoptosis. These include cytosolic and nuclear protein cleavage, protein cross-
linking, cytoskeleton degradation, chromatin condensation, DNA fragmentation, and plasma 
membrane phospholipid rearrangements (e.g. Elmore, 2007). Notably, the process of apoptosis 
and subsequent clearance of apoptosis cells in vivo generally occurs without an inflammatory 
response that may be otherwise generally damaging (Rock & Kono, 2008). 
Generally, the distinct morphological and biochemical changes of apoptosis distinguish it 
from another main form of cell death known as necrosis (Kanduc et al., 2002). Morphologically, 
necrosis is characterized by swelling of organelles and cytoplasm that eventually leads to rupture 
of the plasma membrane, lysis of the cell, and the unorganized release of intracellular contents 
(Häcker, 2000). Necrotic cell death occurs rapidly, independent of energy, and generally without 
physiological regulation. As such, it is sometimes referred to as an “accidental” form of cell 
death and generally only occurs under catastrophic conditions (e.g. abrupt energy crisis or drastic 
physical damage to the cell). In vivo, the unorganized release of intracellular contents can 
damage the surrounding extracellular environment by eliciting an inflammatory response that 
may further exacerbate acute tissue trauma (Rock & Kono, 2008). 
1.2.2 Apoptotic proteolytic activity of Caspases: 
A major family of proteins involved in the regulation of apoptotic cell death are caspases 
(cysteine-dependent aspartate-directed proteases). These proteins are cytosolic proteases 
expressed as a mostly inactive proenzyme or zymogen with an inhibitory N-terminal “pro” 
domain. Under apoptotic conditions, regulated proteolytic processing results in release of the 
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inhibitory domain, initiating the enzyme’s proteolytic activity (Fuentes-Prior & Salvesen, 2004). 
Each caspase enzyme features a cysteine amino acid residue in its active site and catalyzes 
proteolytic cleavage of specific target protein(s) or peptide(s) at the C-terminal side of an 
aspartate residue. The target substrate specificity is determined by the four amino acids that 
precede the cleavage site (i.e. residue-residue-residue-residue-aspartate; Thornburry et al., 1997; 
Talanian et al., 1997).  
Members of the caspase family are categorized as either initiators or executioners of 
apoptosis, with Caspase-2, -8, -9, -10 fitting in the former category and Caspase-3 and to a lesser 
extent -6 and -7 belonging to the latter category in mammals (Cohen, 1997; Kumar, 2007). 
Generally, initiator caspases participate in proteolytic cascades that activate executioner 
caspases. In turn, active executioner caspases cleave a variety of specific protein substrates that 
contribute to intracellular degradation and morphological changes that are characteristic of 
apoptosis (e.g. Earnshaw et al., 1999; Porter & Janicke, 1999; Kumar 2007). Caspase activation 
contributes to cell death in a variety of human diseases (e.g. see review by McIlwain et al., 
2013). 
1.2.3 Mitochondrial involvement in apoptosis: 
There are two main pathways of apoptotic cell death: the “extrinsic” pathway and the 
“intrinsic” pathway. In the extrinsic apoptotic pathway, specific extracellular cell death-inducing 
ligands (e.g. members of the tumour necrosis factor-α family of cytokines) bind to specific 
death-receptors located in the plasma membrane to initiate intracellular cascades of events that 
catalyze apoptotic cell death. In contrast, in the intrinsic apoptotic pathway, intracellular-derived 
signals derived from internal stress (e.g. intracellular dysfunction) stimulate mitochondrial 
release of several proteins that subsequently initiate intracellular cascades leading to apoptosis. 
There can be convergence of the extrinsic and intrinsic apoptosis pathways, with many of the 
extrinsic pathway ligands activating signals that cause mitochondrial release of pro-apoptotic 
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proteins (Elmore, 2007). The mitochondrial contribution to apoptotic cell death is important in a 
variety of pathological disease states, where it contributes to tissue degeneration and organ 
dysfunction (e.g. see citations in Kroemer et al., 2007).   
A pivotal event in mitochondria-mediated apoptosis is the release of the mitochondrial 
protein cytochrome c into the cytosol (Fig. 1.1). Cytochrome c activates a cytosolic cascade of 
molecular events that culminate in the activation of apoptotic machinery leading to cell death.  
Cytochrome c release from mitochondria proceeds by a two-step process, whereby cytochrome c 
first loses its affinity for the inner mitochondrial membrane, and then translocates into the 
cytosol after permeabilization of the outer mitochondrial membrane (Ott et al., 2002). Cytosolic 
cytochrome c binds to the cytosolic protein apoptotic protease activating factor-1 (Apaf-1), 
inducing a conformational change that allows this complex to bind dATP or ATP (Li et al., 
1997). Subsequently, the complex oligomerizes to form the ‘apoptosome’ - a multimeric 
complex of cytochrome c and Apaf-1 (Zou et al., 1999). The initiator caspase Pro-caspase 9 is 
then recruited to the apoptosome, and subsequently cleaved (Li et al., 1997; Zou et al., 1999). 
Active Caspase 9 then proteolytically activates the main executioner Caspase 3, which then 
catalyzes the extensive proteolysis leading to apoptotic cell death (Li et al., 1997: Zou et al., 
1999; Jiang & Wang, 2004). 
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Figure 1.1: Cytochrome c released into the cytosol participates in apoptosome formation 
and subsequent activation of caspases (from Jiang & Wang, 2004). 
 
 In addition to cytochrome c, other pro-apoptotic proteins are released by mitochondria, 
including Smac/Diablo (second-mitochondria derived activator of caspase, or Diablo), 
Omi/HtrA2 (high-temperature-requirement protein A2), endoG (endonuclease G), and AIF 
(apoptosis inducing factor). Smac/Diablo and Omi/HtrA2 act through sequestration and/or 
proteolytic activity to free caspases of inhibitory interactions in the cytosol, thus increasing 
availability for activation (Du et al., 2000; Verhagen et al., 2000; Yang et al., 2003). EndoG and 
AIF each possess nuclease activity and thus catalyze DNA degradation after translocation to the 
nucleus (Li et al., 2001; Susin et al., 1999). Notably, the pro-apoptotic activity these proteins has 
been observed to occur downstream of cytochrome c release, after caspase activation (Adrain et 
al., 2001; Arnoult et al., 2002; Arnoult et al., 2003), again emphasizing the importance of 
cytochrome c release from mitochondria during apoptosis. Since cytochrome c release from 
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mitochondria is a critical early apoptotic event, there is great interest in pharmacologically 
inhibiting this step to prevent apoptotic cell death in certain pathological contexts.  
1.2.4 Cytochrome c – mitochondrial redox activities:  
Cytochrome c is an approximately 12 kDa soluble, positively charged, redox-active 
protein located in the inter membrane space of mitochondria in all aerobic organisms. The 
protein contains a single heme group that is covalently attached to the protein via two thioether 
bridges at Cys14 and Cys17. In the centre of the porphyrin ring of the heme is a single iron atom 
that is normally hexa-coordinated, with four proximal ligands provided by the porphyrin ring of 
the heme structure and two axial ligands provided by His18 and Met80 (see Fig. 1.2 for a visual 
depiction of cytochrome c structure). Importantly, the heme iron can undergo one-electron 
transitions from Fe2
+
 (reduced; ferrous) and Fe3
+
 (oxidized; ferric) states. This redox transition 
allows the heme group to serve as a cofactor for redox activities of the protein.  
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Figure 1.2: Structure of cytochrome c isolated from bovine heart (Protein Data Bank 
accession code 2B4Z; Mirkin et al., 2008).  
Top panel: Ribbon backbone of cytochrome c (green) with stick representations of the heme 
group and axial Met80 and His18 ligands. Bottom panel: Stick representation of the heme group 
with (left) or without (right) axial Met80 and His18 ligands from alternative viewpoints. White, 
blue, red, and yellow sticks respectively represent the locations of carbon, nitrogen, oxygen, and 
sulphur atoms.  Images were generated using Swiss-PDBViewer DeepView v4.1 (Guex & 
Peitsch, 1997). 
 
Cytochrome c’s interactions with the mitochondria-specific class of phospholipids 
cardiolipins (also known as “diacylphosphatidylglycerol”) are of importance for its biological 
activity. These phospholipids are predominantly localized in the inner mitochondrial membrane 
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(Krebs et al., 1979; Gonzalvez & Gottlieb, 2007). With a net positive charge, cytochrome c 
favourably binds the negatively charged cardiolipin head group (Kagan et al., 2006). Cardiolipin 
binding to cytochrome c is thought to involve electrostatic interactions between positively 
charged lysine residues of cytochrome c and the negatively charged phosphate groups on 
cardiolipin, as well as hydrophobic interactions between a polyunsaturated fatty acid residue on 
cardiolipin and a hydrophobic pocket of cytochrome c (Bayir et al, 2006). The former interaction 
involves a loosely bound protein conformation and is believed to necessitate electron transport 
activity (Yin & Zhu, 2012). Alternatively, the hydrophobic interaction is associated with a tightly 
bound conformation with partial unfolding of the protein and is important for mitochondrial 
involvement in apoptosis. This interaction with cardiolipin involves the loss of the Met80-heme 
iron coordination, and opens the heme iron catalytic site to be accessible to small oxidizing 
equivalents, like H2O2 (Kagan et al., 2005; Yin & Zhu, 2012). Using such oxidizing equivalents 
for catalysis, the heme iron exhibits measurable peroxidase activity that appears to be specific to 
bound polyunsaturated species of cardiolipin (Kagan et al., 2005). The accumulation of 
peroxidized cardiolipin species within mitochondria is recognized as an essential event for both 
outer mitochondrial membrane permeabilization during apoptosis, and the loss of cytochrome c 
from the inter membrane space of mitochondria (Ott et al., 2002; Nakagawa, 2004; Kagan et al., 
2005; Petrosillo et al., 2005; Korytowski et al., 2011; Yin & Zhu et al., 2011). 
 
1.3 Oxidative phosphorylation: 
Mitochondria are the sites of aerobic ATP production via oxidative phosphorylation. 
Oxidative phosphorylation centres on the establishment of a proton electrochemical gradient 
across the inner mitochondrial membrane that is used to generate ATP (Mitchell, 1961). In this 
process, electrons derived from the catabolism of nutrients are transported through a step-wise 
series of reduction-oxidation (redox) reactions along protein complexes embedded in the inner 
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mitochondrial membrane, eventually reducing oxygen to water at Complex IV. Energy harvested 
from electron transfer concomitantly drives proton extrusion from the matrix into the inter 
membrane space by Complexes I, III, and IV. The resulting build-up of protons in this 
compartment creates a proton motive force (Δp; units in millivolts), which features an electrical 
component (an electrical gradient, or difference in electrical charge, across the inner 
mitochondrial membrane, “ΔΨm”, referred to as mitochondrial membrane potential) and a 
chemical component (a chemical gradient, or difference in proton concentration across the inner 
mitochondrial membrane, “ΔpH”). This proton motive force is typically -120 to -160 mV within 
intact cells or -180 to -190 mV in isolated mitochondria (Kamo et al., 1979; Haffner et al., 1990; 
Azzone et al., 1984), and is used to drive Complex V (or the “ATP synthase”) to catalyze the 
phosphorylation of ADP into ATP (Noji et al., 1997). Since the reduction of oxygen is the final 
step in the generation of the proton motive force used to synthesize ATP, oxygen consumption is 
said to be coupled to ADP phosphorylation (see Fig. 1.3 below for a schematic illustration of the 
mitochondrial electron transport system and the accompanying description for more details).  
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Fig 1.3: Cartoon depiction of the ultrastructure and oxidative phosphorylation system of 
mitochondria. 
A) Left: Three-dimensional electron tomography image of a brown fat mitochondrion (taken 
from Frey & Mannella, 2000). Right: Cartoon depiction of mitochondrial ultrastructure. Cristae 
(invaginations of the inner mitochondrial membrane and the predominant site of oxidative 
phosphorylation) are depicted in yellow, the inner boundary membrane is depicted in blue, the 
outer mitochondrial membrane in purple, and the mobile electron carrier cytochrome c is 
depicted as a red-coloured circle. The interior blank space is the matrix compartment.  
+ 
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B) Schematic cartoon illustrating the oxidative phosphorylation system within mitochondria. 
Electrons derived from catabolic processes are delivered to Complex I and Complex II (from 
NADH and FADH2, respectively) and then passed on to the mobile lipophilic electron carrier 
molecule ubiquinone (“Q”) embedded within the membrane. Electrons from ubiquinol are 
delivered to Complex III and then passed on to the mobile electron carrier protein cytochrome 
(“cyt”) c located in loose association with the inner membrane in the intermembrane space. 
Subsequently, cytochrome c donates electrons to Complex IV, where they are accepted by 
oxygen (terminal electron acceptor) in its reduction to water. The transport of electrons through 
the system is coupled to the extrusion of protons to the intermembrane space by Complex I, III, 
and IV. The resulting electrochemical gradient across the inner mitochondrial membrane yields a 
proton motive force. The dissipation of this force via proton flow back down the electrochemical 
gradient through Complex V drives ADP phosphorylation to form ATP. 
 
Notably, mitochondrial oxygen consumption is not perfectly coupled to ATP synthesis, 
as protons constitutively “leak” across the inner mitochondrial membrane back into the matrix 
independent of Complex V. Proton leak can also be induced through physiologically-regulated 
processes (Divakaruni & Brand, 2011), but generally is mediated by certain inner mitochondrial 
membrane-spanning proteins (e.g. uncoupling proteins, adenine nucleotide translocase) with 
proton-translocating capability (Erlanson-Albertsson, 2003; Divakaruni & Brand, 2011). 
Importantly, exogenous small molecules or drugs may artificially stimulate proton leak to 
dissipate the proton motive force and uncouple electron transfer from ATP synthesis. For 
example, the chemical carbonylcyanide-ρ-trifluoromethoxyphenylhydrazone (FCCP) mediates 
proton transfer across membranes, and acts as a potent uncoupler of oxidative phosphorylation 
(Terada, 1990). Generally, such protonophoric action can be detrimental to oxidative 
phosphorylation, as ATP synthesis is impaired when there is an insufficient proton motive force.  
Oxidative phosphorylation is a major contributor to oxygen consumption in mammals. In 
the basal state, it is estimated that approximately 90% of total mammalian oxygen consumption 
is by mitochondria (Rolfe & Brown, 1997). Of this percentage, approximately 80% is estimated 
to be coupled to ATP synthesis, whereas approximately 20% is uncoupled by proton leak (Rolfe 
& Brown, 1997). Based on estimates with humans and rats, the brain, heart, liver, and kidney are 
the major oxygen-consuming tissues in the basal state, and largely contribute to whole-
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organismal basal oxygen consumption rate when considering the relatively low proportion of 
their individual mass to total body mass (Rolfe & Brown, 1997). Generally, oxidative 
phosphorylation is the preferred metabolic pathway for ATP production in quiescent or 
differentiated cells (e.g. Lunt & Vander Heiden, 2011). In highly aerobic tissues or cell types, 
disruptions to oxidative phosphorylation can be potentially detrimental to their ability to perform 
their normal function(s), and may even lead to cell death if too severe (e.g. if there is prolonged 
oxygen depletion; Kalogeris et al., 2012). Notably, dissipation of mitochondrial membrane 
potential by drugs is being increasingly recognized as a major mode of drug toxicity that can 
limit drug utility in these tissues (Nadanaciva & Will, 2009). 
Given the importance of oxidative phosphorylation to ATP synthesis, it is important to 
test the functional integrity of this system under experimental conditions of interest (e.g. in the 
presence of a drug candidate). Since electron transport is coupled to proton extrusion across the 
inner mitochondrial membrane in both mitochondria and cells, the rate of mitochondrial oxygen 
consumption can serve as an accurate measure of total proton current (Brand & Nicholls, 2011). 
With the use of an oxygen-sensitive electrode, experiments can be designed to measure proton 
current in isolated mitochondria, permeabilized cells, intact cells, and tissue slices to assess basic 
processes of oxidative phosphorylation, and thus characterize mitochondrial energetic 
(dys)function (Chance & Williams, 1955; reviewed in Brand & Nicholls, 2011). Other ways to 
assess potentially impaired oxidative phosphorylation can include measurements of 
mitochondrial membrane potential, which can be achieved using fluorescent membrane 
permeant-cationic dyes whose mitochondrial uptake/fluorescence are dependent on 
mitochondrial membrane potential (e.g. Perry et al., 2011; Brand & Nicholls, 2011; Nicholls, 
2012).  
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1.4 Glucose metabolism:  
Glucose is a major substrate fueling mammalian energy metabolism. Glucose is 
catabolised by glycolysis, which converts glucose into pyruvate through a series of ten enzyme-
catalyzed reactions within the cytosol. In total, the completion of the pathway generates a net 
yield of two ATP molecules via substrate-level phosphorylation, two molecules of the reduced 
coenzyme nicotinamide adenine dinucleotide (NADH), and two molecules of pyruvate per 
molecule of glucose. The end-product pyruvate can be imported into mitochondria and enter the 
TCA cycle, which generates the reduced intermediates NADH and FADH2 (reduced flavin 
adenine nucleotide) that provide electrons for oxidative phosphorylation for aerobic ATP 
production. Alternatively, pyruvate can remain in the cytosol, where it may be enzymatically 
converted to lactic acid. This latter pathway utilization is referred to as “lactate fermentation”, 
and additionally results in NAD
+
 regeneration necessary to sustain cytosolic ATP production via 
substrate-level phosphorylation. From the perspective of ATP yield, the cellular ATP yield from 
glycolysis alone is relatively low (i.e. 2 net ATP molecules produced per glucose molecule) 
compared to oxidative phosphorylation (i.e. up to approximately 36 ATP molecules per glucose 
molecule) (Pape et al., 2012). Importantly, however, glycolysis intermediates can branch into 
other metabolic pathways (e.g. pentose phosphate shunt) to provide carbon to be used for the 
biosynthesis of macromolecules (e.g. nucelotides, amino acids, lipids) rather than ATP (Lunt & 
Vander Heiden, 2011). 
 
1.5 Proliferating mammalian cells predominantly utilize aerobic glycolysis: 
Proliferating mammalian cells, whether they are cancerous or normal, tend to 
preferentially direct glycolysis-derived pyruvate to lactate rather than to mitochondria for 
oxidative phosphorylation (Vander Heiden et al., 2011). This fermentative metabolism is termed 
“aerobic glycolysis”, as it occurs even in the presence of oxygen. The predominant usage of 
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aerobic glycolysis by such cell types is in contrast to the energy metabolism of non-proliferative, 
differentiated cell types (e.g. neurons, cardiomyocytes), which generally are more reliant on 
oxidative phosphorylation to meet the ATP demands. Mitochondria of proliferative cells 
generally are still fully functional (Vander Heiden et al., 2009; Zheng, 2012). Thus, the increased 
usage of aerobic glycolysis has been proposed to be a metabolic adaptation of proliferative cells 
to serve needs other than ATP production. This is thought to predominantly involve the 
incorporation of glycolytically-derived carbon intermediates into biomass (e.g. nucleotides, 
amino acids, lipids), which is required for the production of daughter cells during cell division 
(Vander Heiden et al., 2009; Mulukutla et al., 2010; Lunt & Vander Heiden, 2011). 
 
1.6 Manipulation of cellular energy metabolism of cultured cells: 
Cell lines are useful tools for studying biological phenomena and in drug development. 
Cultured cells are usually grown under conditions stimulating high rates of proliferation. Under 
these conditions, cultured cells preferentially utilize aerobic glycolysis rather than oxidative 
phosphorylation. This renders them less sensitive to perturbations of oxidative phosphorylation 
than cells with a more aerobic metabolic phenotype (Marroquin et al., 2007). This characteristic 
has important ramifications – prospective drug molecules that perturb oxidative phosphorylation 
may be better tolerated by cells utilizing primarily aerobic glycolysis to meet ATP demand. 
Since glucose is catabolized primarily by aerobic glycolysis in cultured cells, providing 
an alternative carbohydrate source in culture media can influence cellular energy metabolism. 
With this in mind, replacement of glucose with galactose has been used to increase reliance on 
oxidative phosphorylation (e.g. Marroquin et al., 2007). Galactose can be converted to glucose 
for subsequent entry into glycolysis, however, the conversion of a galactose molecule to a 
glucose molecule consumes ATP and therefore prevents a net ATP gain from the glycolytic 
production of pyruvate (Holden et al., 2004). As a result, cells are forced to utilize other 
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metabolic substrates provided in the culture medium for ATP generation. This predominantly 
involves enhanced mitochondrial catabolism of the amino acid glutamine (Meister, 1956; Reitzer 
et al., 1979; Zielke et al., 1976; Kovacevic & McGivan, 1983; Rossignol et al., 2004; 
DeBerardinis et al., 2007). For example, when galactose replaced glucose as the main 
carbohydrate source in the culture medium for HeLa cells, greater than 98% of cellular ATP was 
provided by glutamine oxidation through the TCA cycle (Reitzer et al., 1979). Enhanced 
glutamine utilization for ATP production has been similarly observed with other proliferative 
cells in culture provided with a non-fermentable carbohydrate source, and has been proposed as a 
general phenomenon with proliferative cell types (Zielke et al., 1984; Neerman & Wagner, 
1996).  
With forced reliance on oxidative phosphorylation from enhanced glutamine utilization, 
cells display an elevated aerobic metabolism that includes measurably higher rates of cellular 
oxygen consumption and lowered glycolytic activity (e.g. Rossignol et al., 2004; Marroquin et 
al., 2007; Aguer et al., 2011; Gusdon et al., 2012; Swerdlow et al., 2013). This renders cells more 
dependent on the functional integrity of the mitochondrial energetics system, and consequently 
more sensitive to disrupted oxidative phosphorylation (Marroquin et al., 2007). With this in 
mind, glucose-free, galactose/glutamine-containing media has been used in cell culture studies to 
identify defective mitochondrial respiratory function in cultured cells derived from patients with 
mitochondrial disorders or other diseases (Robinson et al., 1992; Aguer et al., 2011), as well as 
to screen small molecules or drug candidates for mitochondrial energetic toxicity (Marroquin et 
al., 2007; Dykens et al., 2008; Rana et al., 2011). 
 
1.7 Mitophagy – process of selective mitochondrial degradation: 
 Autophagy (from the Greek words auto “self”, and phagein “to eat”) is a physiological 
process that involves the orderly degradation of intracellular contents for recycling purposes (De 
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Duve, 1966; Levine & Klioncky, 2004). The process features a program of sequential events that 
includes sequestration of intracellular proteins and organelles by double-membrane vesicles 
(termed “autophagosomes”) and delivery to acidic lysosomes, where hydrolytic degradation 
takes place to liberate products that may be recycled for use in anabolic or catabolic processes 
(Mizushima, 2007). In addition to the bulk degradation of intracellular contents (termed 
‘macroautophagy”), autophagy may be selective for specific organelles, including mitochondria. 
The mitochondria-selective form of autophagy is termed “mitophagy” (Lemasters, 2005).  
Mitophagy has been increasingly recognized as an important process for homeostatic 
quality control of mitochondria. It is involved in routine mitochondrial turnover, and can also be 
stimulated when mitochondria are defective or have impaired function (Ashrafi & Schwarz, 
2012). For example, depolarization of the mitochondrial membrane potential by chemical 
uncoupling can lead to the selective recruitment of mitophagy machinery and subsequent 
lysosomal degradation of mitochondria within cells (Narendra et al., 2008; Narendra et al., 2010; 
Sun et al., 2012). In this context, mitophagy serve as an important coordinated role with other 
cellular processes (e.g. mitochondrial biogenesis) that ensure necessary mitochondrial content is 
maintained within the cell (Detmer & Chan, 2007). Experimentally, mitophagy can be identified 
in a number of ways, including co-localization of mitochondria with autophagosome machinery 
and delivery into lysosomes (Ding & Yin, 2012). Additionally, mitophagy can be reflected as an 
apparent decrease in mitochondria-specific content (e.g. mitochondrial proteins, mitochondrial 
DNA, cardiolipin, etc) within cells (Ding & Yin, 2012).  
 
1.8 Mitochondrial dynamics in energetics, mitophagy, and cell death: 
 
Due in large part to static, electron microscopy techniques, mitochondria have been 
classically looked upon as singular, discrete organelles. However, the advent of live-cell 
confocal microscopy has yielded a more accurate depiction of mitochondrial morphology. It is 
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now apparent that mitochondria exist in a complex network representing a dynamic equilibrium 
between fusion and fission (reviewed in McBride et al., 2006). Generally, their morphology can 
fluctuate between a highly fused, interconnected reticulum or network and a fragmented state 
with smaller networks and/or discrete, individual puncta or rod-like structures. The ongoing 
shaping of mitochondrial network morphology is tightly controlled by various proteins that 
catalyze pro-fusion or pro-fission events on either the outer or inner mitochondrial membranes 
(e.g. reviewed in Soubannier & McBride, 2009). Interestingly, mitochondrial morphology 
appears to be closely associated with function in energy metabolism, their own quality control 
processes that cooperates with intracellular machinery, cell death, and other cellular activities 
(Babbar & Sheikh, 2013).   
Energetic status of mitochondria within cells has been observed to be associated with 
different morphologies. In human ovarian cancer HeLa cells forced to have increased reliance on 
oxidative phosphorylation for ATP production, a more highly fused, elongated mitochondrial 
network existed in comparison to when cultured in a glucose-containing, fermentable medium 
(Rossignol et al., 2004). In rat kidney epithelial cells, elevated ATP production was observed 
when the mitochondrial network was present in a highly fused state at the G1-S transition phase 
of the cell cycle (Mitra et al., 2009). Conversely, a more fragmented mitochondrial network has 
generally been observed in cultured cells exposed to chemical uncouplers of oxidative 
phosphorylation or inhibitors of respiratory chain components that disrupt mitochondrial 
membrane potential and ATP production (e.g. Legros et al., 2002; Ishihara et al., 2003; Benard et 
al., 2004; De Vos et al., 2005; Barsoum et al., 2006; Liot et al., 2009; Liu & Hajnóczky, 2011; 
Toyama et al., 2016). These findings suggest that fused mitochondrial network is more 
conducive for increased ATP production, whereas a fragmented network is associated with 
decreased energetic efficiency and lowered ATP production. The exact functional advantage(s) 
to explain increased mitochondrial ATP production when mitochondria are in a more fused state 
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are unclear, but may involve increased efficiency (i.e. coupling) of the system as a result of 
greater complementation of biomaterials involved in oxidative phosphorylation (e.g. metabolites) 
and electrical continuity (e.g. Youle & van der Bliek, 2012). Regardless of the exact reason(s), 
identifying changes in mitochondrial morphology can be useful indices of possible changes to 
energetic properties of mitochondria within a cell. For example, observing fragmentation of 
mitochondria in response to an exogenously applied drug candidate of interest may be indicative 
that the molecule exerts toxicity to mitochondrial bioenergetics. 
Other examples of mitochondrial morphology changes within cells can include both 
processes of mitochondrial quality control and apoptotic cell death. The fission of mitochondria 
with sufficiently impaired energetics (e.g. prolonged dissipation of membrane potential) enables 
selective degradation of mitochondria from the network, possibly to maintain a healthy pool of 
proper functioning mitochondria (Twig et al., 2008; Ashrafi & Schwarz, 2012). Under lethal 
conditions, fragmentation of the mitochondrial network facilitates events that stimulate apoptotic 
cell death (Karbowski & Youle, 2003; Suen et al., 2008). The involvement of mitochondrial 
morphology under these two processes is presently an active area of research. Nonetheless, 
identifying mitochondrial shape changes under conditions of interest can provide useful clues 
that such processes are potentially occurring.  
 
1.9 Targeting small molecules to mitochondria: 
Given the importance of mitochondrial events in apoptosis, directly targeting 
mitochondrial apoptotic processes with small molecules could be a way to prevent cell death 
where appropriate. The mitochondrial membrane potential resulting from a functioning electron 
transport system causes the interior compartment of mitochondria to be substantially more 
negatively charged with respect to the extra-mitochondrial environment (Kamo et al., 1979; 
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Azzone et al., 1984; Haraldsdóttir et al., 2012). This membrane potential is a potentially 
exploitable property for drug delivery to mitochondria.  
A general class of molecules that feature chemical properties conducive for 
mitochondrial targeting is lipophilic cations. These molecules possess a positive charge and yet 
are relatively lipid soluble. Consequently, they can essentially be “electrophoresed” across 
biological membranes through simple diffusion rather than protein-mediated import. The 
accumulation of a singly positively charged lipophilic cation is proportional to membrane 
potential (Ψ) (Ross & Murphy, 2011), as described by the Nernst equation:  
∆Ψ = 61.5𝑙𝑜𝑔10 (
[𝑐𝑎𝑡𝑖𝑜𝑛 𝑖𝑛]
[𝑐𝑎𝑡𝑖𝑜𝑛 𝑜𝑢𝑡]
)        𝑎𝑡 37°𝐶 
 This relationship translates to an approximate ten-fold accumulation of the cation for 
every approximate 60 mV difference in electrical potential across a membrane. The plasma 
membrane typically possesses a membrane potential of -30 to -60 mV (negative inside; Azzone 
et al., 1984), meaning that lipophilic cations will accumulate approximately five-to-ten-fold 
within the cytosol. Since the mitochondrial membrane potential in live cells is typically -120 to -
160 mV (Kamo et al., 1979), lipophilic cations further accumulate several-hundred-fold within 
mitochondria (Ross & Murphy, 2011).  
One lipophilic cation that has been well-utilized for mitochondrial targeting is 
triphenylphosphonium (TPP), which features a single positive charge that is screened or 
delocalized over a large hydrophobic surface area (see Fig. 1.4 for schematic depiction of 
cellular and mitochondrial uptake of a prototypical TPP-containing molecule). The first use of a 
TPP molecule in mitochondrial biology came in the late 1960’s by Vladimir Skulachev and 
colleagues, who showed that a TPP-cation accumulated within mitochondria during respiration 
due to the large mitochondrial membrane potential (Liberman et al., 1969; Bakeeva et al., 1970). 
Over the next several decades, TPP-cations were often used in conjugation with TPP-compatible 
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electrodes as a tool to investigate mitochondrial membrane potential (e.g. Kamo et al., 1979; 
Nobes et al., 1990). However, the use of TPP cations in biomedical applications was pioneered 
beginning in the mid-1990’s by Mike Murphy, who reasoned that attachment of bioactive 
compounds to TPP cations could be used to deliver mitochondria-targeted therapeutics (Murphy, 
1997). His research group later synthesized a mitochondria-targeted antioxidant consisting of a 
TPP-moiety attached to the antioxidant ubiquinone – termed “MitoQ” (Kelso et al., 2001). The 
interactions with mitochondria of this molecule and other similar derivatives have been well-
characterized (e.g. Kelso et al., 2001; Asin-Cayuela et al., 2004; Murphy & Smith, 2011). These 
molecules are able to effectively limit both oxidant levels within mitochondria and accumulation 
of mitochondria/intracellular oxidative damage, and can exert protective effects in a variety of 
pathological contexts both in vitro and in vivo (reviewed in Smith & Murphy, 2010). The proof 
of efficacy of this small molecule, together with a growing understanding of fundamental 
mitochondrial biochemical processes in mammalian health and disease, have subsequently 
garnered vast interest in developing novel TPP-cation based mitochondrial therapeutics with 
potentially greater target specificity and enhanced modulatory properties.  
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Figure 1.4: Uptake of a prototypical TPP-conjugated compound. The prototypical TPP-
molecule conjugated to an “X” bioactive moiety first accumulates 5-10-fold in the cytosol as a 
result of the plasma membrane potential (ΔΨp), and then further accumulates several h undred-
fold in mitochondria as a result of the mitochondrial membrane potential (ΔΨm). Figure taken 
from Ross et al. (2005). 
 
 
1.10 TPP-IOA is a mitochondria-targeted inhibitor of apoptosis: 
Considering that the peroxidase activity exhibited by cytochrome c/cardiolipin complexes 
is crucial to the release of pro-apoptotic factors, the design of inhibitory agents to disrupt this 
complex has been proposed to be a promising novel strategy for modulating apoptosis (Kagan et 
al., 2009b). Once cytochrome c and cardiolipin are tightly bound, peroxidase activity in 
cytochrome c is induced through partial unfolding of the protein and weakening of the heme-iron 
coordination bond to Met80. This structural change allows for improved access of the heme 
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catalytic site to small molecules, like H2O2, that can provide oxidizing equivalents that feed 
catalysis (Kagan et al., 2005; Kagan et al., 2009b). With this in mind, blocking the availability of 
the heme catalytic site has been proposed as one strategy to diminish the peroxidase function of 
this complex (Kagan et al., 2009b; Atkinson et al., 2011).  
Imidazole-substituted long chain fatty acids have been invented for this purpose (Kagan 
et al., 2009b; Atkinson et al., 2011). These molecules were initially intended for potential use as 
radioprotectors or radiomitigators, as lethal γ–irradiation exposure in vivo can cause massive cell 
death through the mitochondrial apoptotic pathway (Macia i Garau et al., 2011). They were 
designed on the basis of their carboxyl group being able to interact with Lys residues on 
cytochrome c, and the hydrophobic acyl chain being able to protrude into the hydrophobic 
pocket within the protein that provides accessibility to the heme iron site. Consequently, the 
imidazole attached to the oleate chain could potentially interact with the heme-iron of the 
catalytic site, thus fulfilling heme-iron hexa-coordination and lessening the catalytic site’s 
availability (Kagan et al., 2009b; Atkinson et al., 2011). Indeed, imidazole-substituted oleic 
(IOA) and stearic acids (ISA) with the imidazole moiety located 7 carbons away from the 
terminal methyl group were able to interact with the haem-iron of cytochrome c (Atkinson et al., 
2011). Furthermore, these imidazole-fatty acid derivatives were shown to be effective inhibitors 
of the peroxidase activity of pure cytochrome c/tetra-oleoyl-cardiolipin complexes (Atkinson et 
al., 2011). 
To achieve mitochondrial targeting of these inhibitors, they were chemically conjugated 
to a TPP moiety (specifically a 3-hydroxypropyl-triphenylphosphonium molecule). Indeed, TPP-
IOA (3-hydroxypropyl-triphenylphosphonium-conjugated imidazole substituted oleic acid; Fig. 
1.5a) administration to cultured mouse embryonic cells via addition to culture medium resulted 
in rapid accumulation of TPP-IOA within mitochondria (Atkinson et al., 2011). Notably, in 
addition to the fully intact molecule being present, the two hydrolysis products, 3-
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hydroxypropyl-TPP (Fig. 1.5b) and the imidazole oleic acid moiety (Fig. 1.5c), were each also 
detectable (the relative abundances are unclear from this report), indicating TPP-IOA can 
undergo intracellular endogenous hydrolytic processing (Atkinson et al., 2011). Additionally, a 
single bolus intraperitoneal injection of TPP-IOA to live mice resulted in rapid detectable 
accumulation within radiosensitive tissues of interest (bone marrow, small intestine; Atkinson et 
al., 2011), indicating successful in vivo uptake.  
 
 
 
 
Figure 1.5: Chemical structures of the mitochondria-targeted imidazole fatty acid 
derivative a) TPP-IOA (3-hydroxypropyl-triphenylphosphonium-conjugated imidazole 
substituted oleic acid), and its hydrolysis products b) 3-hydroxypropyl-
triphenylphosphonium and c) imidazole-substituted oleic acid. 
 
 
Notably, IOA conjugation to the TPP-moiety via esterification (therefore free anionic 
carboxyl group is not available) did not affect proximity of the imidazole ligand to the heme 
iron, and nor did it significantly affect the ability for inhibition of peroxidase activity of pure 
cytochrome c/cardiolipin complexes (Atkinson et al., 2011). This suggests that electrostatic 
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interactions with Lys residues of cytochrome c are actually not important for binding of the 
molecule, while the hydrophobic interaction predominates. Subsequently, in cultured mouse 
embryonic fibroblasts exposed to lethal doses of γ–irradiation, TPP-IOA suppressed cytosolic 
cytochrome c accumulation, Caspase-3 cleavage, phosphatidylserine externalization, and 
increased the overall survival (Atkinson et al., 2011). TPP-IOA also limited the abundance of 
apoptotic mouse lung endothelial cells in response to the mitochondrial respiratory poison and 
apoptotic trigger rotenone, suggesting the possibility that the anti-apoptotic capabilities may not 
be stimulus- or cell-type specific. Importantly, the protective effects observed in vitro 
successfully translated in vivo, as TPP-IOA profoundly increased whole-organism survival in a 
rodent model of lethal γ–radiation exposure (Atkinson et al., 2011). 
Subsequently, Maddalena (2012) investigated whether TPP-IOA has the potential to limit 
cell loss resulting from ischemia/reperfusion-like injury (e.g. akin to neuronal cell death 
following brain ischemia/reperfusion), which involves apoptotic cell loss through the 
mitochondrial pathway of apoptosis (e.g. Honda et al., 2005; Kalogeris et al., 2012).  Here, an in 
vitro cell culture model was utilized in which SH-SY5Y human neuroblastoma cells were 
transiently deprived of both oxygen and glucose (oxygen/glucose deprivation model; OGD). 
With TPP-IOA addition following the insult, a detectable prevention of cell loss was observable 
after a recovery period in comparison to vehicle control-treated cells (Fig. 1.6).  
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Figure 1.6: TPP-IOA limits the extent of cell loss induced from a transient ischemia-
reperfusion-like injury (oxygen/glucose deprivation (OGD) model) in cultured SH-SY5Y 
human neuroblastoma cells.  
A) Brightfield microscopy images of SH-SY5Y cells in culture under basal culture conditions 
either immediately prior to (left panel) or 24 hours after recovery (right panel) from eight hours 
of oxygen- and glucose-deprivation (OGD) reveal that TPP-IOA (5 µM; administered 
immediately upon restoration of both oxygen and glucose levels) can prevent cell loss resulting 
from a transient period of OGD. Images are representative fields of views under 100x total 
magnification. B) Water-soluble tetrazolium-1 (WST-1)-based viability assay (performed 24 
hours from the onset of OGD recovery) reveals that TPP-IOA improves viability of cells 
subjected to OGD. Data were standardized to the vehicle control group. * represents p-value < 
0.05 (Student’s t-test). Figure was adapted from Maddalena (2012). 
 
1.11 TPP-IOA’s interaction with energetics:  
In the only previous assessment of TPP-IOA’s impact on mitochondrial energetics, total 
cellular ATP levels were measured 48 hours from the addition of TPP-IOA to proliferative 
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mouse embryonic cells under standard culture conditions. Here, an absence of an effect was 
reported (Note: TPP-IOA concentrations and data not provided; Atkinson et al., 2011). However, 
considering the predominant use of aerobic glycolysis/lactate fermentation of proliferative cells 
and resultant decreased sensitivity to toxins affecting mitochondrial energetics (Marroquin et al., 
2007), the interpretation of TPP-IOA’s impact on mitochondrial energetics from the existing data 
is limited. The interpretation may be further limited by the long duration between TPP-IOA 
addition and measurements (48 hours), as compensatory transcriptional adaptations to decreased 
mitochondrial ATP output are possible in this timeframe (e.g. proliferation of mitochondria or 
downregulation of ATP consuming processes, etc, caused via activation of the major intracellular 
energy sensing protein AMP-kinase; Hardie, 2011). Thus, TPP-IOA’s interaction with 
mitochondrial energetics is unclear from existing data.  
Crucially, many cell types of great biomedical interest with limited regenerative 
capability are typically highly aerobic and reliant on mitochondria to meet their ATP demand. 
With this in mind, it is important to note that the existing in vitro data for TPP-IOA’s protective 
effects comes from proliferative cells cultured under standard conditions that are heavily 
glycolytic. Additionally, the existing in vivo protective data comes from a pathological state 
(radiation poisoning) in which the predominantly affected cells are highly proliferative and 
predominantly utilize aerobic glycolysis (Macia i Garau et al., 2011; Lunt & Vander Heiden, 
2011). Therefore, there is no definitive evidence that TPP-IOA can be effective at limiting cell 
death in highly aerobically-active cell types that are otherwise more sensitive to acute drug-
induced toxicities to mitochondrial energetics. With this in mind, understanding TPP-IOA’s 
interaction with mitochondrial energetics is important for potentially expanding its anti-apoptotic 
utility to other in vivo pathological states affecting highly aerobic tissues (e.g. heart, brain). 
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1.12 Project Objectives, Proposed Approaches, and General Hypothesis: 
Given the prevention of cell death previously observed in various in vitro and in vivo 
models, the mitochondria-targeted small molecule TPP-IOA has potential as an effective 
therapeutic agent in other pathologies involving cell death through the mitochondrial pathway of 
apoptosis. The pathological contexts in which TPP-IOA has been demonstrably effective to date 
have involved pathologies and/or experimental models where the predominantly affected cell 
types (i.e. proliferative gastrointestinal tract cells, hematopoietic cells, and various cells in 
culture) meet their ATP demands through fermentative metabolic pathways rather than oxidative 
phosphorylation. Crucially, many cell types of great biomedical interest (e.g. neurons, 
cardiomyocytes) feature a highly aerobic energy metabolism, and are reliant on oxidative 
phosphorylation. Since TPP-IOA is targeted to mitochondria and interacts directly with 
cytochrome c, it has the potential to directly interfere with oxidative phosphorylation. However, 
TPP-IOA’s direct interaction with oxidative phosphorylation is unknown. If TPP-IOA does 
indeed perturb activity of mitochondrial energetics, its protective efficacy may be limited in cell 
types that are heavily reliant on oxidative phosphorylation, which could limit potential future 
therapeutic applications.  With this in mind, the overall general aim of this thesis was to 
investigate the anti-apoptotic utility of TPP-IOA from a bioenergetics perspective. The 
experimental objectives and accompanying in vitro approaches are as follows: 
1) Since the target protein, cytochrome c, also possesses an electron transfer activity that is 
critical for oxidative phosphorylation, does the interaction of TPP-IOA with cytochrome 
c affect this activity? Furthermore, if this occurs, then does it occur at concentrations 
similar to those required to inhibit cytochrome c’s pro-apoptotic oxidative activity? For 
investigations aimed at the direct effects of TPP-IOA on its target protein, biochemical 
assay systems containing purified cytochrome c were used. A spectrophotometry-based 
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assay measuring reduction activity and a spectrofluorometry-based assay of peroxidase 
activity were each utilized. 
2) Since the target organelle, the mitochondrion, is the major site of ATP generation through 
oxidative phosphorylation, can TPP-IOA interfere with mitochondrial oxidative 
phosphorylation? Furthermore, if such disruption occurs, then does it occur at 
concentrations similar to those required for inhibition of pro-apoptotic oxidative activity? 
For investigations aimed at elucidating the direct effects of TPP-IOA on its target 
organelle, closed-system respirometry measuring mitochondrial respiratory states and a 
spectrofluorometry-based assay of pro-apoptotic oxidative activity were utilized with 
isolated rat liver mitochondria.  
3) Does TPP-IOA interfere with energetics or related mitochondrial physiology in intact 
cells? If there is any such impact, then does cellular reliance on mitochondrial oxidative 
phosphorylation limit TPP-IOA’s ability to prevent cell death in response to apoptotic 
stimuli? A cell culture approach was used to address these questions. To assess 
energetics, a combination of closed-system respirometry for metabolic rate measurements 
and confocal imaging-based qualitative assessment of mitochondrial membrane potential 
were performed. Additionally, a combination of confocal microscopy, immunoblot, and a 
spectrophotometric enzyme activity assay were used to determine effects of TPP-IOA 
and related molecules on mitochondrial network morphology. Finally, apoptotic cell 
death was studied in cells cultured with different culture media compositions to increase 
reliance on oxidative phosphorylation.  Cell death was evoked by an apoptotic stimulus 
and cell viability was assessed using a Trypan blue exclusion assay together with a 
spectrofluorometric activity assay of the apoptosis marker Caspase-3.  
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Overall, it is hypothesized that TPP-IOA can interfere with energetic processes of 
mitochondria, and that this could limit its protective efficacy in cells that are reliant on 
mitochondrial oxidative phosphorylation. 
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Chapter 2.0 - Experimental Methodology: 
 
2.1 Materials: 
3-hydroxypropyl-triphenylphosphonium (Catalogue #S860166), cytochrome c (from 
bovine heart; Cat. # C3131), cardiolipin solution (from bovine heart; ≥80% polyunsaturated fatty 
acid content, primarily linoleic acid; in ethanol Cat. #C1649), ascorbic acid, tert-butyl 
hydroperoxide aqueous solution (70% w/w; Cat. #B2633), Dulbecco’s Modified Eagle Medium 
powdered media with glucose (4500 mg/L), L-glutamine, and sodium pyruvate (Cat. #D7777), 
supplement-free Dulbecco’s Modified Eagle Medium powdered media (Catalogue #5030), fetal 
bovine serum (Cat. #F1051), nonessential amino acids, penicillin/streptomycin solution, 0.25% 
trypsin/EDTA solution, and bovine serum albumin (BSA) were obtained from Sigma-Aldrich 
(St. Louis, USA).  
Dimethylsulfoxide (DMSO), DL-dithiothreitol (DTT), Bradford reagent, D-galactose, L-
glutamine, HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), and Trypan Blue were 
obtained from BioShop (Burlington, ON, Canada).  
Amplex Red reagent (10-Acetyl-3,7-dihydroxyphenoxazine; Item 10010469) was 
obtained from Cayman Chemical (Ann Arbor, MI, USA).  
The Caspase-3 fluorogenic substrate Ac-DEVD-AMC (Cat. #556449) and Caspase-3 
inhibitor Ac-DEVD-CHO (Cat. #556465) were both obtained from BD Biosciences (Franklin 
Lakes, NJ, USA).  
Tissue culture dishes (100x20 mm & 60x15 mm) and cell scrapers were obtained from 
Sarstedt, Inc (Newton, SC, USA).  
MitoTracker Red CMXRos and Lipofectamine 2000 transfection reagent were purchased 
from Life Technologies Incorporated (Burlington, ON, Canada).  
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Goat (C-11) polyclonal Actin antibody (Product #sr-1615) raised against a peptide 
fragment of the C-terminus of human Actin was purchased from Santa Cruz Biotechnology, Inc. 
(Dallas, TX, USA).  
Rabbit polyclonal VDAC antibody (Product #600-401-882) raised against a synthetic 
peptide corresponding to amino acids 185 – 197 of human VDAC1 and infrared dye-conjugated 
secondary (IgG) antibodies to rabbit (Cat. # 611-132-122) and goat (Cat. #605-732-125) were all 
purchased from Rockland Immunochemicals (Gilbertsville, PA, USA). 
 Unless otherwise indicated, all other chemicals, reagents, and solutions were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), BioSHOP (Burlington, ON, Canada), or Fisher 
Scientific (Mississauga, ON, Canada).  
 
2.2 Preparation of reagents, stock solutions, and buffers: 
TPP-IOA and TPP-OA were obtained from Dr. Jeffrey Atkinson (Brock University; see 
Atkinson et al., 2011 for chemical synthesis of TPP-IOA). TPP-IOA, TPP-OA, and 3-
hydroxypropyl-TPP (Fig. 2.1 below) were dissolved in sterile-filtered DMSO. Stock solutions of 
each were made via serial dilutions and stored as small volume aliquots (typically 35 µL) at -
20°C and protected from light. Phosphate-buffered saline (PBS; 1X) consisted of 137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH adjusted to 7.4. PBS-t (1X) consisted of 
PBS with 0.1% (v/v) Tween-20 detergent. For isolation of mitochondria (section 2.2.5 below), 
SHE buffer consisted of 250 mM sucrose, 10 mM HEPES, and 1mM EGTA, final pH adjusted to 
7.5, and SHE+BSA buffer consisted of SHE buffer with 0.5% (w/v) bovine serum albumin 
(delipidated, fraction V), final pH adjusted to 7.5. Mitochondrial respiration buffer consisted of 
125 mM sucrose, 65 mM KCl, 10 mM HEPES, and 2 mM KH2PO4, pH adjusted to 7.2. Trypan 
blue solution (0.4% w/v) was prepared in 0.81% NaCl and 0.06% K2HPO4. Cell lysis buffer (1X) 
consisted of 10 mM Tris-HCl, 10 mM NaH2PO4, 130 mM NaCl, 1% Triton-X-100, 10 mM 
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sodium pyrophosphate, pH 7.5. Caspase-3 activity assay buffer (1X) consisted of 20 mM HEPES 
(pH 7.5), 10% glycerol, 2 mM DTT. MitoTracker Red CMXRos, and TMRM each at 1 mM 
were made using DMSO and stored at -20 in small aliquots. All aqueous buffers/solutions were 
prepared using ultrapure deionized water obtained from a Milli-Q water purification system 
(MilliPore Ltd, Etobicoke, ON, Canada).  
 
 
 
Figure 2.1: Chemical structures of A) TPP-IOA, B) TPP-OA (TPP-IOA  
devoid of an imidazole group), and C) 3-hydroxypropyl-TPP. 
 
2.3 Cytochrome c/cardiolipin complex peroxidase activity: 
Peroxidase activity of pure cytochrome c in the presence of cardiolipin was assessed with 
Amplex Red reagent [similarly to as described in Atkinson et al., (2011) and Birk et al., (2013)] 
using a Varian Cary Eclipse fluorescence spectrophotometer equipped with microplate reader 
(Agilent Technologies, Santa Clara, CA, USA). This spectrofluorometric assay measures the 
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formation of resorufin – the fluorescent oxidation product of Amplex Red reagent generated in 
the presence of peroxidase enzymatic activity (Zhou et al., 1997).  To perform the assay, 
cytochrome c (1 μM; from bovine heart) was incubated within HEPES buffer (20 mM, pH 7.4) 
with purified cardiolipin (15 μM; ≥80% polyunsaturated fatty acid content, primarily linoleic 
acid, from bovine heart) with or without the TPP-conjugated molecules for 10 minutes while 
hidden from light, before addition of hydrogen peroxide and Amplex Red reagent each at a final 
concentration of 50 μM. The formation rate of resorufin was continuously measured over 
approximately 10 minutes following peroxide and Amplex Red additions using excitation and 
emission wavelengths of 525 nm and 590 nm, respectively. Maximal reaction rates [Arbitrary 
Fluorescence Units (AFU) per minute] were calculated from the initial linear range of resorufin 
formation using the instrument software Cary Eclipse Kinetics (Walnut Creek, USA). The final 
amount of DMSO in each assay was 0.1%. The assay was performed at room temperature with 
protection from light.  
 
2.4 Isolation of liver mitochondria: 
Mitochondria from liver tissue of 10 - 12 month old female Long Evans rats (obtained 
from Charles River Laboratories, Sherbrooke, QE, Canada; whole body weight ranged from 
approximately 350 grams – 450 grams) were isolated essentially as described in Stuart et al., 
(2005). Animals were euthanized in accordance with protocols approved by Brock University 
Animal Care Committee, which involved overdose by isoflurane inhalation and subsequent heart 
excision. All steps of mitochondria isolations were completed on ice or at 4°C. Liver tissue was 
immediately excised, washed several times with PBS, then finely minced using a straight edge 
razor blade, and transferred to a 50 mL centrifuge tube before being rinsed several times with 
PBS to remove blood. Minced tissue was then re-suspended in SHE + BSA buffer and 
centrifuged at 1,000 x g for 10 minutes. The resulting blood-containing supernatant was 
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discarded, and the pellet was re-suspended in fresh SHE+BSA buffer. The tissue suspension was 
then homogenized by hand using a pre-chilled Potter-Elvehjem polytetrafluoroethylene (PTFE) 
pestle and glass tube. Tissue homogenate was centrifuged at 500 x g for 12 minutes, and the 
resulting supernatant was subsequently transferred to a fresh centrifuge tube and centrifuged at 
9,500 x g for 10 minutes. The pellet containing the mitochondrial fraction was gently re-
suspended in SHE buffer and centrifuged again at 9,500 x g for 10 minutes. The resulting pellet 
containing the final mitochondrial fraction was gently re-suspended in SHE buffer. Protein 
concentration of the final mitochondrial suspension was then determined spectrophotometrically 
using the Bradford reagent/method with BSA as the protein standard. The entire isolation process 
from tissue harvest to protein concentration determination was performed within approximately 
120 minutes.  The final mitochondria-containing suspension was stored on ice throughout the 
duration of subsequent experiments (i.e. peroxidase activity and respiration assays) that were 
performed within 10 hours of the isolation. 
 
2.5 Mitochondrial peroxidase activity: 
Measurements of peroxidase activity of freshly isolated mitochondria were performed 
essentially as in Atkinson et al. (2011) using an Amplex-based assay. Here, the organic peroxide 
tert-butyl hydroperoxide (tBOOH) was used as both an inducer of cytochrome c peroxidase 
(interacts similarly as cardiolipin; Belikova et al., 2006; Belikova et al., 2009; Yanamala et al., 
2014) and a source of oxidizing equivalents rather than hydrogen peroxide to avoid 
decomposition by endogenously high levels of the hydrogen peroxide-detoxifying enzyme 
catalase within liver mitochondria. Mitochondria (0.25 mg/mL) freshly isolated from rat liver 
were incubated in HEPES buffer (20 mM, pH 7.4) with or without the TPP-conjugated 
molecules for ten minutes before addition of 2mM tBOOH and 50 μM Amplex Red reagent. The 
final amount of DMSO in each assay was 0.05%. The maximal formation rate of resorufin as a 
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proxy for peroxidase activity was calculated as in section 2.2.3, above. All peroxidase activity 
assays were performed with 96-well microplates maintained at room temperature under ambient 
and dark conditions. 
 
2.6 Reduction of cytochrome c by ascorbate: 
Ascorbate was used to reduce cytochrome c due to it possessing a lower redox potential 
than cytochrome c (Lide, 1994) and thus a propensity to readily reduce the heme iron. 
Cytochrome c (1 μM final concentration), and immediately thereafter TPP-IOA, 3HP-TPP, or 
TPP-OA, were added to a 1.5 mL polystyrene cuvette containing HEPES buffer (20 mM, pH 
7.4). The final amount of DMSO present in each assay cuvette was 0.1%. The mixture was 
briefly vortexed and then allowed to incubate protected from light at room temperature under 
ambient conditions for 10 minutes. The cuvette was subsequently placed inside a Varian Cary-
100 Bio UV-Vis spectrophotometer, wherein 1 µM ascorbic acid was added and the entire 
solution was rapidly mixed using a micropipette. The formation of an absorption peak at 550 nm, 
the characteristic peak of reduced heme iron of cytochrome c (Moore & Pettigrew, 1990), was 
recorded over approximately 10 minutes. The maximal rate of reduction (ΔAbsorbance per 
minute) was calculated from the initial linear range of 550 nm peak formation using the 
instrument software Cary WinUV Kinetics (Walnut Creek, USA). 
 
2.7 Mitochondrial respiration measurements:  
 Oxygen consumption rates of freshly isolated rat liver mitochondria were measured at 
25°C within a thermostatically-controlled closed chamber using a Clark-type oxygen electrode 
(Rank Brothers Dual Digital Model 20 Respirometer; Bottisham, United Kingdom) attached to a 
polygraph recorder. Prior to commencing measurements, the device was calibrated using air-
saturated mitochondrial respiration buffer warmed to the experimental temperature. One 
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milligram per millilitre suspension of mitochondria in respiration buffer was first added to the 
respirometer chamber, followed by addition of TPP-IOA or 3HP-TPP. The final percentage of 
DMSO in the chamber was 0.1%. After 5 minutes of being open to atmosphere, the chamber was 
capped and a stable reading of baseline oxygen consumption rate was obtained.  
To subsequently assess mitochondrial respiratory states, an experimental paradigm 
similar in principle to the classic experiments of Chance and Williams (1955) was followed. 
Briefly, the respiratory substrates glutamate and malate (5 mM final concentration of each) were 
each added to the closed chamber to achieve State 2 respiration. After reaching a stable rate of 
oxygen consumption, a finite amount of ADP (250 µM final) was added to stimulate State 3 
respiration (representative of ADP-phosphorylating respiration or oxidative phosphorylation 
capacity). State 4 respiration (representative of non-phosphorylating respiration) was determined 
from the stable slowed rate apparent following State 3 respiration. Notably, oxygen levels in the 
chamber were ensured to not drop below approximately 20% saturation in order to avoid 
potential back diffusion of oxygen into the chamber and a resultant artefactual slowed respiration 
rate. To measure fully uncoupled respiration rates (representative of electron transport system 
capacity), the same experimental paradigm was followed except the chemical protonophore 
FCCP at a final concentration of 2 µM was added to the chamber after a steady State 2 
respiration rate was reached. All chart slope values from the polygraph recordings were 
converted to nanomol O2 consumed · minute
-1
 · milligram mitochondrial protein
-1
. 
 
2.8 Cell culture: 
SH-SY5Y human neuroblastoma cells, and in some instances C2C12 murine myoblasts, 
were used for experiments. SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA, USA) and 
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 4500 mg/L glucose, 4 mM L-glutamine, 1 mM sodium 
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pyruvate, 2x MEM nonessential amino acid solution, and penicillin (50 I.U./mL) / streptomycin 
(50 µg/mL) solution. Cells were cultured in a humidified 5% CO2 atmosphere within a Thermo 
Forma Series II water-jacketed CO2 incubator maintained at 37°C. Cells were grown and 
expanded in culture on 100 mm diameter culture plates and subcultured at a split ratio of 1:5 
once approximately 80% confluence was reached. To subculture, growth medium was removed, 
plates were rinsed with PBS, and then 0.25% Trypsin/EDTA solution was added to plates for 
approximately 3 minutes to detach cells from the plates. Once cells were visibly detached, FBS-
containing culture media was added to neutralize trypsin action. Cell suspensions were then 
collected into conical tubes, and centrifuged for 5 minutes at 240 x g. The resulting supernatant 
was discarded, and the cell pellet was re-suspended with fresh growth media. One millilitre of 
the resulting cell suspension was added throughout the growth surface of each new culture plate 
already containing freshly added growth media, and plates were placed back into the culture 
incubator.  
For experiments involving galactose-containing culture medium, SH-SY5Y cells grown 
in glucose-containing media (as above) were harvested using the splitting procedure above and 
were seeded onto 100 mm culture plates containing medium that consisted of glucose-free 
DMEM supplemented with 10% fetal bovine serum, 10 mM galactose, 6 mM L-glutamine, 10 
mM HEPES, 1 mM sodium pyruvate, 2x MEM nonessential amino acid solution, and penicillin 
(50 I.U/mL) / streptomycin (50 µg/mL) solution. These cells were cultured under the same 
ambient conditions as cells grown in glucose-containing medium for five-to-six days prior to 
harvest for subsequent experiments (i.e. respiration or cell death assays). 
For all cell culture work, any buffers, solutions, or media used were pre-warmed to 37°C 
in an Isotemp 110 water bath (Fisher Scientific, Mississauga, ON, Canada) for at least 1 hour 
prior to use. All cell culture work was performed under sterile conditions inside of a Class II 
Type A2 biological safety cabinet (Esco Inc., Hatboro, PA, USA). 
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2.9 Measurements of total and apoptotic cell death: 
2.9.1 Induction of cell death/apoptosis with hydrogen peroxide: 
SH-SY5Y cells were harvested from 100 mm culture plates via trypsinization and seeded 
onto either 6-well plates for measurements of total cell death or 60 mm plates for measurements 
of Caspase-3 activity following exposure to hydrogen peroxide. To evoke cell death, culture 
medium on plates was replaced with same culture medium containing freshly added hydrogen 
peroxide with or without freshly added TPP-IOA or other experimental compounds of interest. 
The hydrogen peroxide/TPP-IOA addition was made by adding freshly diluted stock solution to 
culture media within a conical tube, which was then immediately mixed by gentle inversion, 
before addition to culture plates. The final percentage of DMSO in the media was 0.1%. A set of 
preliminary dose-response experiments were performed to determine the concentration of 
hydrogen peroxide that evoked approximately 50% total cell death (assessed by the Trypan blue 
exclusion assay and performed as indicated the proceeding section) in cells cultured within both 
types of media (glucose-containing or glucose-free/galactose-/glutamine-containing DMEM). 
 
2.9.2 Trypan Blue exclusion assay for total cell death: 
Twenty-four hours from the onset of hydrogen peroxide exposure, measurements of the 
number of living SH-SY5Y cells were made using the Trypan Blue exclusion assay. Floating 
cells present within the culture media and adherent cells harvested via trypsinization were 
combined into conical tubes and the cell pellet resulting from centrifugation (5 minutes at 240 x 
g) was re-suspended in 100 µL of media. Ten µL of this cell suspension was then diluted with 
190 µL of 0.4% (w/v) Trypan Blue solution (dilution factor = 20), which was then briefly 
vortexed and allowed to incubate for 3 minutes at room temperature. Subsequently, the mixture 
was briefly re-suspended and 10 µL was loaded onto a hemocytometer (Hausser Scientific, 
Horsham, PA, USA) with a cover slip in place. The hemocytometer was viewed with a Hund 
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Wetzlar Wilovert Inverted Phase-Contrast microscope (Fisher Scientific, Mississauga, ON, 
Canada), and the number of cells in the four large corner squares and large middle square were 
counted. Cells that appeared stained blue were considered non-viable/dead, while cells excluding 
the Trypan Blue dye appeared colourless/opaque and were recorded as living. The concentration 
of living cells in the initial 100 µL cell suspension was calculated by the following equation: 
# Live cells/mL = (mean number of live cells per square) x (dilution factor) x (10,000)  
The total number of living cells in the initial 100 µL cell suspension was then determined 
by multiplying the amount of live cells per millilitre by the total volume of the initial cell 
suspension. In every independent experiment performed, the calculated values for each 
experimental sample were normalized to the mean value of the non-treated control samples. 
 
2.9.3 Caspase-3 activity assay for apoptosis: 
Cells were harvested 12 hours from the onset of hydrogen peroxide exposure for 
measurements of Caspase-3 activity in whole-cell lysates using the fluorogenic Caspase-3 
proteolytic substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC).  
To first harvest cells, medium containing floating cells was collected into conical tubes 
that were then centrifuged at 500 x g for 3 minutes, while ice-cold PBS was added the culture 
plates containing adherent cells that were then immediately collected via scraping the plate 
surface with a plate scraper. Both scraped cells and the corresponding pelleted floating cells were 
combined within microcentrifuge tubes kept on ice that were then centrifuged at 500 x g, 4°C for 
3 minutes with an IEC Micromax RF refrigerated microcentrifuge (Fisher Scientific). The 
resulting cell pellets were flash frozen in liquid nitrogen and stored at -80°C.  
To prepare whole-cell lysates, cell pellets were re-suspended in a small volume (120 µL) 
of ice-cold cell lysis buffer and allowed to incubate on ice for 30 minutes with routine vortexing 
(5 seconds in duration at setting 5; VWR Mini Vortexer) every 5 minutes. Subsequently, lysates 
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were centrifuged at 10,000 x g, 4°C for 10 minutes and the resulting supernatants were used for 
subsequent assays. Protein concentrations of lysates were determined via the Bradford 
reagent/assay with BSA as the protein standard using a UV-Vis spectrophotometer.  
Prior to performing assays of Caspase-3 activity, all samples were diluted to a 
concentration of 1.5 µg/µL so that equal volume of each assay reagent could be used between 
samples. Twenty-five micrograms of whole-cell lysate was used per Caspase-3 activity 
measurement performed within 96-well spectrofluorometric microplates. To each assay well, 
freshly prepared protease assay buffer (consisting of 20 mM HEPES (pH 7.5), 10% glycerol, and 
2 mM DTT), 25 µg sample lysate, and 20 µg Ac-DEVD-AMC were added in succession and the 
microplate was incubated for 3 hours at 37°C protected from light within a microplate warmer. 
After this period, the microplate was scanned using a Varian Cary Eclipse fluorescence 
spectrophotometer with set excitation and emission wavelengths of 360 nm and 445 nm, 
respectively. Emitted AMC fluorescence, which becomes spectrofluorometrically detectable 
when AMC is released from the Ac-DEVD peptide as a result of characteristic Caspase-3-
catalyzed proteolytic cleavage (Talanian et al., 1997), was used as a quantifiable measure of 
Caspase-3 activity for each sample. Each sample lysate was assayed in quadruplicate wells that 
were averaged together to obtain a single value of Caspase-3 activity (arbitrary AMC 
fluorescence intensity units) per experimental treatment. Each assay performed included a 
measure of background fluorescence emission in lysate-free wells that was subtracted from all 
sample readings.  
 
2.10 Establishment of a stable SH-SY5Y cell line expressing modified emerald fluorescent 
protein-labelled mitochondria: 
The plasmid mEmerald-Mito-7 encoding a gene for modified emerald fluorescent protein 
(mEFP) targeted to the mitochondrial matrix compartment via N-terminal mitochondrial 
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targeting sequence from subunit VIII of human Complex IV/cytochrome c oxidase (Planchon et 
al., 2011) was a gift from Michael Davidson (Florida State University). The plasmid contained a 
kanamycin-resistance gene for bacterial selection and geneticin (G418)-resistance gene for 
mammalian cell selection. The plasmid was obtained from Addgene (plasmid # 54160) as an E. 
coli agar stab culture.  To recover the plasmid DNA, the bacteria were streaked onto an agar 
plate containing 50 mg/mL kanamycin, which was then kept overnight within a 37°C incubator. 
Single colonies were then selected and amplified in overnight liquid cultures at 37°C in a C25KC 
shaker incubator (New Brunswick Scientific, Edinson, NJ, USA). Eighteen hours later, these 
cultures were removed and plasmid DNA was isolated and purified using a plasmid DNA 
Miniprep Kit (Norgen Biotek, Thorold, ON, Canada). Both purity (260 nm/280 nm absorbance 
ratio) and concentration of the resulting isolated plasmid mEmerald-Mito-7 DNA were assessed 
using a NanoPhotometer instrument. 
A stably transfected SH-SY5Y cell line expressing mEmerald-Mito-7 was created, herein 
referred to as “SH-SY5Y-mito-mEFP”. For this, a 24-well plate was seeded with 90,000 SH-
SY5Y cells per well. Approximately 36 hours later, at which point wells were approximately 
80% confluent, cells were transfected using Lipofectamine 2000 reagent following the 
manufacturer’s instructions. Briefly, Lipofectamine 2000 reagent and plasmid DNA were each 
diluted in serum-free/antibiotic-free DMEM (transfection media) and then combined to form 
plasmid DNA-lipid complexes. After a 5 minute incubation period, the diluted mixture was 
added to wells. Five different combinations of plasmid DNA:Lipofectamine reagent in 
quadruplicate wells were used (µg:µL): 0.5:0.5, 1:1, 1.5:1.5, 1:3, 1:1.5. Approximately 24 hours 
after the transfection procedure, transfection media was replaced with selection media (DMEM 
with 10% FBS, 2x nonessential amino acids, and G418 at 400 µg/mL; the G418 concentration 
was determined in a prior screening experiment to be the minimum lethal dose for SH-SY5Y 
cells in 24-well plates). Selection medium was refreshed every other day. After approximately 10 
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days of selection, the concentration of G418 in culture media was dropped to100 µg/mL. Culture 
media with 100 µg/mL G418 freshly added was used thereafter to maintain selection. The stable 
cell line generated using the transfection combination of 1 µg plasmid DNA / 3 µL 
Lipofectamine 2000 reagent was used for all subsequent imaging experiments. To confirm 
mitochondrial localization of the mEFP, colocalization of mEFP signal with the mitochondria-
targeted fluorescent dye MitoTracker RedCMXRos was detected using confocal microscopy (see 
Appendix I Fig. AI.5.1; protocols for imaging and staining are described below). 
 
2.11 Fluorescence microscopy: 
 Confocal images of both live and fixed cells were obtained using a Carl Zeiss Axio 
Observer.Z1 inverted light/epifluorescence microscope equipped with ApoTome.2 optical 
sectioning and a Hamamatsu ORCA-Flash4.0 V2 digital camera. Cells were cultured on MatTek 
35 mm poly-D-lysine-coated glass bottom culture dishes with culture media devoid of phenol red 
for imaging and plates were viewed with a Plan-Apochromat 63x/1.40 Oil DIC M27 microscope 
objective. For live cell imaging, the microscope stage and objectives were maintained at 37°C, 
with temperature control achieved through TempModule S-controlled stage heater and objective 
heater (PeCon, Erbach, Germany). A humidified 5% CO2 environment was also maintained on 
the stage through tubing connected to a humidified CO2 culture incubator. Fixed cells were 
imaged under ambient conditions. Blue fluorescence (i.e. for Hoechst 33342 signal) was detected 
using a fluorescence channel possessing excitation and emission wavelength filter sets of 335 – 
383 nm and 420 – 470 nm, respectively, with set excitation and emission wavelengths of 353 nm 
and 465 nm, respectively (Zeiss Item# 411003-0002-000). Green fluorescence (i.e. for mito-
mEFP signal) was detected using a fluorescence channel possessing excitation and emission 
wavelength filter sets of 450 – 490 nm and 500 – 550 nm, respectively, with set excitation and 
emission wavelengths of 488 nm and 509 nm, respectively (Zeiss Item# 411003-0004-000). Red 
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fluorescence (i.e. for TMRM and MitoTracker Red CMXRos signals) was detected using a 
fluorescence channel with excitation and emission wavelength filter sets of 540 – 552 nm and 
590 – 660 nm, respectively, with set excitation and emission wavelengths of 587 nm and 610 
nm, respectively (Zeiss Item# 411003-0010-000). Both the intensity of fluorescence illumination 
achieved via an X-Cite 120LED light source and camera exposure times were held constant 
between experimental groups across experiments. Z-stack series consisted typically of 30 – 40 
slices, each 0.25 – 0.3 µm apart, and were rendered into single 2D images using the “extended 
depth of focus” processing tool using Zeiss Zen 2 (blue edition) microscopy software. 
 
2.12 Mitochondrial and nuclear labelling: 
Mitochondria and nuclei were labelled with MitoTracker Red CMXRos and Hoechst 
33342, respectively, by following manufacturer’s protocols. Briefly, to label mitochondria and 
nuclei in some experiments, cells were incubated within their culture incubator for 30 minutes 
with phenol red-free DMEM containing freshly added 50 nM MitoTracker Red CMXRos with or 
without 500 ng/mL Hoechst 33342. Immediately after staining, plates were washed three times 
with dye-free culture media to remove excess dye before imaging.   
 
2.13 Measurements of mitochondrial membrane potential: 
Tetramethylrhodamine methyl ester (TMRM) dye was used to semi-quantitatively assess 
mitochondrial membrane potential in SH-SY5Y cells through confocal microscopy. Plates of 
cells were given imaging media containing freshly added 30 nM TMRM and then placed back in 
the culture incubator for 45 minutes to allow for dye equilibration before imaging. Images of 
individual cells were obtained before and after experimental treatments at several time points. To 
quantify changes in mitochondrial membrane potential, changes in fluorescence intensities that 
took into account cytosolic background fluorescence were measured using ImageJ/FIJI software. 
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2.14 Quantitative analysis of mitochondrial morphology: 
To quantitatively analyze mitochondrial morphology in live-cell confocal microscopy 
images, a custom-made image processing algorithm compiled into ImageJ macro format 
(“Mitochondrial Network Analysis, Version 1.0.0”, Valente 2016, unpublished; see Appendix II 
for more details) was used. Components of the processing algorithm were inspired by that of 
Leonard et al., (2015) and consisted of freely-available ImageJ image processing tools compiled 
into a series of automated steps to allow for an objective and automated process. The processing 
steps ultimately generated a skeletonized depiction of mitochondria in single live cell images that 
was compatible for quantitative analysis. 
Briefly, the raw confocal microscopy images were subjected to deconvolution using the 
Diffraction Point Spread Function 3D plugin together with the DeconvolutionJ plugin. To 
improve contrast between all mitochondrial structures and background in the deconvolved 
image, contrast limited adaptive histogram equalization (CLAHE) was subsequently performed. 
Through preliminary analysis trials, it was determined that use of deconvolution and CLAHE 
together as processing tools rather than each tool alone ultimately yielded the most accurate 
mitochondrial skeleton, and therefore both tools were included in the processing step. In the 
resulting processed image, using the default black and white threshold algorithm of ImageJ, 
fluorescent mitochondrial signal was subjected to thresholding in order to eliminate relatively 
weak signal capable of generating artifact. The resulting image was then made binary, such that 
mitochondrial signal became uniformly white and everywhere else uniformly black. Using the 
Skeletonize 3D plugin, the binary image was subsequently converted to a skeleton image in 
which mitochondrial signal was converted to lines of one pixel in width. From the skeletonized 
mitochondrial signal, skeleton structures were classified as either individuals or networks. 
Individuals were considered skeletons that did not demonstrate any sort of branching (i.e. either 
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puncta or rods, or extended tubules), whereas networks were considered skeletons containing at 
least one branching point. All resulting quantitative mitochondrial measures were analyzed on a 
“per cell” basis.  
 
2.15 Cellular respiration measurements: 
Respiration measurements of intact SH-SY5Y cells were performed using a Clark-type 
oxygen electrode (Rank Brothers Dual Digital Model 20 Respirometer; Bottisham, UK) attached 
to a polygraph recorder, essentially as in Robb et al., (2012). Briefly, cells from one 100 mm 
culture plate were harvested via trypsinization, centrifuged at 240 x g for 3 minutes, re-
suspended in 1 mL of culture media (serving as respiration buffer), and then placed into a 
thermostatically-controlled chamber maintained at 37°C attached to the respirometer. The 
chamber was capped and the rate of oxygen consumption was measured over a 5-10 minute 
period. All respiration rates were converted to nmol O2 consumed·minute
-1
·10
6
 cells
-1
. 
Immediately following measurements, the cell suspension was recovered in a 1.5 mL 
microcentrifuge tube. A small volume (20 µL) of sample was taken to determine the total 
number of living cells using the Trypan blue exclusion assay, while the remainder of the sample 
was centrifuged for several minutes at approximately 2200 x g using a Fisher Scientific benchtop 
minicentrifuge. The supernatant was discarded and the resulting cell pellet was flash frozen in 
liquid nitrogen and then stored at -80°C for later lysate preparation and experimental analysis 
(i.e. protein concentration determination, citrate synthase activity measurements and immunoblot 
experiments; below).  
 
2.16 Whole-cell lysate preparation: 
 Harvested cell pellets were lysed by incubation in freshly prepared ice-cold lysis buffer 
(10 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 2 mM dithiothreitol, 0.4 % 
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phenylmethylsulfonyl fluoride, 40 % (v/v/) glycerol, 0.5 % (v/v) Nonident P40 detergent) with 
periodic sonication (Ultrasonic Inc., Sonicator W-375; setting 5) for one hour on ice. Following 
this, the resulting suspensions were centrifuged at 10 000 x g at 4°C for ten minutes using a 
benchtop minicentrifuge. The resulting supernatants (i.e. the whole-cell lysates) were kept and 
protein concentrations were determined using the Bradford method using BSA as the protein 
standard. All whole-cell lysates were stored at -80°C. 
 
2.17 Citrate synthase activity assay: 
 Maximal citrate synthase activity of whole-cell lysates was measured using a Bio-Tek 
PowerWave Microplate UV-Vis spectrophotometer (Winooski, VT, USA) at 30°C, essentially as 
in Brown et al., (2007). The activity assay was based on coupling the rate-limiting activity of 
citrate synthase to the irreversible formation of thionitrobenzoic acid (TNB) from 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB; Sere, 1969). Assay buffer consisted of 50 mM Tris pH 
8.0, 500 µM DTNB, 100 µM acetyl-coenzyme A, and 1 µg lysate protein. Citrate synthase 
activity was monitored at 412 nm. After measuring background activity over a period of 3 
minutes, 500 µM oxaloacetate was added to initiate the reaction and the absorbance at 412 nm 
was followed over approximately 10 minutes. 
 
2.18 Immunoblots: 
 Equal amounts of protein (30 µg) from each whole-cell lysate were separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; gels consisted of a 4% 
polyacrylamide top stacking layer and 12% polyacrylamide bottom resolving layer) within a Bio-
Rad Mini-PROTEAN Tetra Cell apparatus. Prior to running the gel, whole-cell lysates were 
mixed 1:1 (v/v) with loading dye containing 10% (v/v)/200 mM DTT and were heated at 90°C 
for 5 minutes. Following electrophoresis, the separated proteins were blotted from the gel onto a 
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polyvinylidene fluoride membrane using a Bio-Rad Trans-Blot semi-dry transfer apparatus. 
Blotted membranes were blocked for one hour at room temperature with a 5% (w/v) non-fat skim 
milk/PBS-t solution to limit non-specific antibody binding. For antibody incubation, membranes 
were separately incubated with anti-VDAC (1:500; w/v) overnight on a rotisserie  at 4°C, washed 
with PBS-t (5 cycles of 5 minutes duration), then incubated with an infrared fluorophore-
conjugated rabbit antibody (1:2500; w/v) for 2 hours at room temperature. The same membranes 
were later probed with anti-Actin (1:250; w/v) overnight 4°C as a protein loading/transfer 
control, washed with PBS-t (5 cycles of 5 minutes duration), and subsequently incubated with an 
infrared fluorophore-conjugated goat antibody (1:2500; w/v) for 2 hours at room temperature. 
After each secondary antibody incubation, the membranes were visualized using an Odyssey 
infrared imaging system (LI-COR Biosciences). Densities of protein bands were quantified using 
the “Gel Analysis” tool of ImageJ software and were standardized to the value of one 
experimental sample. 
 
2.19 Statistical Analyses: 
 All statistical analyses were performed using GraphPad Prism 5 software (San Diego, 
USA). T-tests (one-tailed) were performed on data sets containing two experimental groups, 
whereas one-way ANOVAs were performed for data sets containing three or more experimental 
groups. Paired t-tests or repeated measures one-way ANOVAs were used whenever possible, as 
indicated in figure descriptions. A p-value of < 0.05 was considered significant for all statistical 
tests.  When statistical significance in data sets was observed from one-way ANOVAs, post-hoc 
analysis was performed using Tukey’s honestly significant difference (HSD) test. Non-linear 
regression with least squares fit was used for determination of I.C.50 values from concentration-
response curves with log-transformed concentration values. 
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Chapter 3.0 – Results: 
 
3.1 Inhibition of cytochrome c/cardiolipin complex and mitochondrial peroxidase activities: 
To independently verify TPP-IOA’s (Fig. 2.1A) previously reported ability to inhibit the 
pro-apoptotic peroxidase activity of cytochrome c (Atkinson et al., 2011), peroxidase activities 
of purified cytochrome c/cardiolipin complexes and isolated mitochondria were determined (Fig. 
3.1). In the absence of cardiolipin, cytochrome c (1 µM) catalyzed resorufin formation at a rate 
of 2491 ± 187 arbitrary fluorescence units (A.F.U.) per minute (Fig. 3.1A,B). In the presence of 
tetralinoleoylcardiolipin (15 µM), the rate of cytochrome c (1 µM)-catalyzed resorufin formation 
increased to 9210 ± 444 A.F.U. per minute (Fig. 3.1A,B). The enhancement of cytochrome c 
peroxidase activity observed here in the presence of tetralinoleoylcardiolipin is consistent with 
the well-established mechanism by which cardiolipin binding to cytochrome c causes structural 
changes within the protein that result in greater accessibility of the heme iron catalytic site for 
catalysis (e.g. Kagan et al., 2005, Belikova et al., 2006).  
As expected, TPP-IOA dose-dependently diminished the rate of resorufin formation of 
the cytochrome c/cardiolipin solution, indicating inhibition of peroxidase activity (Fig. 3.1C). 
This finding is consistent with initial published reports (Atkinson et al., 2011) showing that TPP-
IOA is an effective inhibitor of cytochrome c peroxidase activity. 
To determine that the cytochrome c peroxidase inhibition of TPP-IOA is due to the 
strategically placed imidazole group of the oleic acid moiety, measurements were repeated with 
one of two control molecules. TPP-oleic acid has identical structure but lacks the inhibitory 
imidazole group along the fatty acyl chain (Fig. 2.1B).  3-hydroxypropyl-TPP (3HP-TPP) is the 
mitochondria-targeting moiety of TPP-IOA that remains after endogenous cleavage (Fig. 2.1C; 
Atkinson et al., 2011).  Both molecules were tested at the concentrations at which TPP-IOA 
elicited approximately half maximal (0.5 µM; or TPP-IOA to cytochrome c ratio of 0.5:1) and 
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maximal (10 µM; or TPP-IOA to cytochrome c ratio of 10:1) inhibition (Fig. 3.1D). If the 
imidazole group placed on the acyl chain of TPP-IOA is indeed responsible for conferring 
inhibition of cytochrome c/cardiolipin peroxidase activity, then there should be no inhibition 
when the imidazole group is absent. Compared to the vehicle control (0.1% DMSO), TPP-OA 
did not exert significant inhibition of peroxidase activity at the two concentrations tested (both p-
values > 0.05 versus non-treated control, one-way ANOVA with Tukey’s HSD post-hoc test). 
These findings confirm that the imidazole group of TPP-IOA is indeed the major component 
driving inhibition of cytochrome c’s peroxidase activity. Additionally, 3HP-TPP did not inhibit 
peroxidase activity at either concentration (both p-values > 0.05 versus non-treated control, one-
way ANOVA with Tukey’s HSD post-hoc test), indicating that the TPP-containing moiety 
resulting from endogenous processing of TPP-IOA does not interfere with cytochrome c 
peroxidase activity at concentrations equivalent to those at which TPP-IOA is effective. 
Altogether, these findings indicate that TPP-IOA, by virtue of the strategically placed inhibitory 
imidazole along its oleic acyl chain, is a potent and direct inhibitor of the peroxidase activity of 
cytochrome c.  
 The ability of TPP-IOA to inhibit peroxidase activity in freshly isolated intact liver 
mitochondria was also assessed using an Amplex red-based assay system. Resorufin formation 
was significantly suppressed by TPP-IOA at both 5 µM (corresponding to 20 nmol TPP-IOA per 
mg mitochondrial protein; 2418 ± 502 resorufin formed per minute) and 10 µM (corresponding 
to 40 nmol TPP-IOA per mg mitochondrial protein; 1548 ± 245 resorufin formed per min) 
compared to the non-treated control group (3505 ± 601 resorufin formed per minute; Fig. 3.1E; 
p-values both < 0.05, repeated measures one-way ANOVA with Tukey’s HSD post-hoc test). On 
the basis of prior reports indicating cytochrome c to be present in adult rat liver mitochondria at 
approximately 0.21 nmol per mg mitochondrial protein (Wainio, 1970; Petrosillo et al., 2003), 
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these findings indicate that higher amounts of TPP-IOA are required to inhibit peroxidase 
activity in isolated mitochondria than with the purified protein.  
The effect of 3-hydroxypropyl-TPP on peroxidase activity of isolated mitochondria was 
also tested over a similar concentration range (0.5 – 10 µM; or 10 - 40 nmol per mg 
mitochondrial protein). Compared to the non-treated control group, resorufin formation was not 
significantly inhibited at any of the concentrations tested (p-values > 0.05 for each concentration, 
repeated measures one-way ANOVA with Tukey’s HSD post-hoc test; Fig. 3.1E). This, along 
with the lack of inhibitory effect in the above experiments with purified cytochrome c, suggests 
that 3-hydroxypropyl-TPP does not inhibit peroxidase activity of mitochondria. Moreover, these 
findings further indicate that the imidazole-containing oleic moiety of TPP-IOA is responsible 
for the inhibition of mitochondrial peroxidase activity. 
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Figure 3.1: Inhibition of purified cytochrome c and mitochondrial peroxidase activity by 
TPP-IOA and related TPP-containing molecules.  
A) Representative spectrofluorometric kinetic traces of resorufin formation catalyzed by 
cytochrome c in the absence or presence of cardiolipin. B) Quantification of maximal resorufin 
formation rate from initial linear range of kinetic traces indicates that cardiolipin induces 
peroxidase activity of purified cytochrome c. Bars represent means + SEM from 27 or 29 total 
replicates from ten separate experimental trials performed over two independent experiments. 
*** = p-value < 0.001 (unpaired Student’s t-test). C) TPP-IOA dose-dependently inhibits 
peroxidase activity of cardiolipin-induced cytochrome c peroxidase activity. Data points 
represent means ± SEM from six replicates from two independent experimental trials. D) At 
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effective inhibitory concentrations of TPP-IOA against cytochrome c peroxidase activity, 3HP-
TPP and TPP-OA each do not elicit inhibition. Bars represent means + SEM from 6 -12 total 
replicates from two independent experimental trials. Data were standardized to Vehicle control 
(0.1% DMSO) values. *** = p-value < 0.001 compared to Vehicle control (one-way ANOVA 
with Tukey’s HSD post-hoc test). E) TPP-IOA inhibits peroxidase activity of isolated 
mitochondria from rat liver, while 3HP-TPP does not over the same concentration range. Bars 
represent means + SEM from four independent mitochondrial preparations each measured in at 
least sextuplicate. * = p-value < 0.05, *** = p-value < 0.001 compared to Control (repeated 
measures one-way ANOVA with Tukey’s HSD post-hoc test). In A – E, peroxidase activity 
(F.A.U./minute) was spectrofluorometrically determined from the initial linear formation rate of 
the fluorescent oxidation product of Amplex Red reagent, resorufin (ex. 525 nm/ em. 590 nm). 
Note: In C & D, the concentrations on the x-axis also correspond to the molar ratio of TPP-IOA 
to cytochrome c. 
 
3.2 Interference with cytochrome c reduction: 
 
 Beyond its role as the catalytic site for cytochrome c’s pro-apoptotic peroxidase activity, 
the heme iron within cytochrome c serves as the redox active site for electron transfer from 
Complex III to Complex IV of the mitochondrial electron transport system. Given that TPP-IOA 
physically interacts with cytochrome c and presents a ligand (i.e. imidazole) to the heme iron, 
TPP-IOA may also interfere with the protein’s normal electron transfer activity in oxidative 
phosphorylation. To determine whether TPP-IOA interferes with the reduction activity of 
cytochrome c, a spectrophotometric assay measuring the reduction of purified (ferri)cytochrome 
c (Fe3
+
) to (ferro)cytochrome c (Fe2
+
) was performed (Fig. 3.2A; representative experimental 
spectrophotometric trace). In this assay, the rate of cytochrome c reduction by ascorbate in the 
presence of DMSO was 0.0218 ± 0.0004 arbitrary absorbance units per minute. The rate of 
cytochrome c reduction by ascorbate was increasingly inhibited by increasing concentrations of 
TPP-IOA (Fig. 3.2B), indicating that TPP-IOA can interfere with the ability of cytochrome c’s 
heme iron to accept electrons.  
To determine if either 3-hydroxypropyl-TPP (3HP-TPP) or TPP-oleic acid (TPP-OA) 
exhibits similar interference, the rates of cytochrome c reduction by ascorbate in the presence of 
either of these molecules at the approximate half maximal inhibitory TPP-IOA dose (5 µM) were 
compared. The rate of cytochrome c reduction was slowed in the presence of either 3HP-TPP or 
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TPP-OA, however the magnitudes of interference also significantly differed between TPP-IOA, 
TPP-OA, and 3HP-TPP (Fig. 3.2C; p-values < 0.001 between each group; one-way ANOVA 
with Tukey’s HSD post-hoc test). 3HP-TPP appeared to elicit minor inhibition of cytochrome c 
reduction rate (0.0169 ± 0.0016 arbitrary absorbance units per minute), while both TPP-OA 
(0.00304 ± 0.0002 arbitrary absorbance units per minute) and TPP-IOA (0.0123 ± 0.0005 
arbitrary absorbance units per minute) significantly inhibited this activity. TPP-OA, devoid of an 
imidazole ligand along its oleic acyl chain, evoked the strongest inhibition of cytochrome c 
reduction. Taken together, these findings reveal that TPP-IOA can disrupt the electron accepting 
activity of cytochrome c that is required for its function in oxidative phosphorylation.  Moreover, 
such interference is likely driven by the oleic acyl chain of the molecule, since TPP-OA alone 
was a highly effective inhibitor of this activity. 
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Figure 3.2: Interference by TPP-IOA and related TPP-containing molecules with reduction 
of purified cytochrome c by ascorbate.  
A) Representative spectrophotometric kinetic trace (550 nm) of the reduction of purified 
(ferri)cytochrome c by ascorbate. Ascorbate (1 µM) was added to cytochrome c (1 µM) within 
HEPES buffer after approximately two minutes to initiate reduction, and the reaction was 
allowed to proceed for several subsequent minutes. The assay shown was performed in the 
presence DMSO (0.1 %; Vehicle control for TPP- conjugated molecules). B) TPP-IOA dose-
dependently interferes with the rate of reduction of cytochrome c by ascorbate. Reduction rates 
were calculated from the initial linear range after ascorbate addition. Data points represent means 
± SEM from 4 – 9 total replicates from two independent experiments. C) At the approximate 
I.C.50 value of TPP-IOA, TPP-OA elicits greater interference to cytochrome c reduction by 
ascorbate while 3HP-TPP elicits a less intense effect. Bars represent means + SEM from 4 -9 
total replicates from two independent experimental trials. *** = p-value < 0.001 compared to 
DMSO (one-way ANOVA with Tukey’s HSD post-hoc test). All groups had significantly 
different mean values from one another (not shown on graph; p-value < 0.001 for each 
comparison, one-way ANOVA with Tukey’s HSD post-hoc test) Note: in both B & C, the 
concentrations also correspond to the molar ratio of TPP-IOA to cytochrome c. 
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3.3 Therapeutic efficacy of TPP-IOA at the level of its isolated protein target: 
For drug candidates, the dose ratio between therapeutic and toxic effects is known as the 
therapeutic index.  It can be the ratio of the respective doses that cause 50% inhibition of the 
effects of interest (Muller & Milton, 2012). Since the above findings demonstrated inhibition of 
both the cardiolipin-induced peroxidase activity and the electron accepting activity of 
cytochrome c by TPP-IOA, it is instructive to compare the relative dose-dependencies of these 
two effects to determine TPP-IOA’s therapeutic index. Therefore, I.C.50 values were determined 
as 0.65 ± 0.06 µM or nmol TPP-IOA per nmol cytochrome c (R
2
 = 0.9711; non-linear regression 
with least squares fit) and 5.28 ± 1.12 µM or nmol TPP-IOA per nmol cytochrome c (R
2
 = 
0.9768; non-linear regression with least squares fit) for peroxidase activity inhibition (Fig. 
3.3A,B red squares) and reduction inhibition (Fig. 3.3A,B blue circles), respectively. 
Additionally, these respective I.C.50 values differed significantly from one another (p-value 
<0.0001; extra-sum-of-squares F-test). From these values, an approximate therapeutic index of 
8.12 was calculated. Although no universally acceptable “safe” therapeutic index value exists 
(Muller & Milton, 2012), this result nonetheless indicates that, at the level of its specific protein 
target, there is a protective window for TPP-IOA when considering its potentially therapeutic 
anti-apoptotic effect and its presumably undesired interference with bioenergetics activity.  
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Figure 3.3: Merged dose-response relationships for TPP-IOA’s inhibitory effects on both 
peroxidase activity and reduction of purified cytochrome c reveal the existence of a 
therapeutic window.  
A) Non-transformed and B) semi-log transformed dose-response curves for TPP-IOA’s 
inhibition of both peroxidase activity (squares) and reduction activity (circles) of purified 
cytochrome c. Red squares represent means ± SEM of cardiolipin-induced cytochrome c 
peroxidase activity from six replicates performed over two independent experiments (data 
derived from Fig. 3.1B. Blue circles represent reduction of cytochrome c by ascorbate in the 
presence of TPP-IOA from 4 – 9 total replicates performed over two independent experiments 
(data derived from Fig. 3.2B). Data points within each set were standardized to respective 
vehicle (0.1% DMSO) control group values. Non-linear regression analysis revealed I.C.50 
values for the two responses differed significantly (p-value <0.0001; extra-sum-of-squares F-
test). Note: the micromolar concentrations of TPP-IOA indicated on the x-axes are equivalent to 
the ratio of nmol TPP-IOA to nmol cytochrome c. 
 
 
3.4 Interference with mitochondrial respiration: 
 There is no information regarding TPP-IOA’s effect on mitochondrial respiration, 
however, previous studies have demonstrated that molecules with similar chemical structure to 
TPP-IOA, such as oleic acid and TPP-containing linker molecules, can perturb mitochondrial 
respiration (Schönfeld et al., 1989, see refs in Wojtczak & Schönfeld, 1993, see refs in Di Paolo 
& Lorusso, 2006, Reily et al., 2013, & Trnka et al., 2015). Given these reports and the finding 
above that TPP-IOA can interfere with cytochrome c’s reduction activity, it was hypothesized 
that TPP-IOA could affect oxidative phosphorylation. To test this hypothesis, respiratory states 
of freshly isolated mitochondria from rat liver were measured using closed-system respirometry 
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(Fig. 3.4). The respiratory control ratio (RCR; State 3 respiration divided by State 4 respiration) 
takes into account all functional aspects of oxidative phosphorylation components, and is 
indicative of the extent to which oxygen consumption and ATP production are coupled. If TPP-
IOA interferes with any functional component of oxidative phosphorylation, then a reduction in 
the RCR would be observed. In the presence of vehicle control (DMSO), isolated liver 
mitochondria exhibited an RCR of 5.69 ± 0.34. TPP-IOA reduced the RCR (Fig. 3.4A), with 
significantly lower values observed at both 5 µM and 10 µM TPP-IOA (3.79 ± 0.24 and 2.56 ± 
0.16, respectively; p-value <0.05 for both, one-way ANOVA with Tukey’s HSD post-hoc test). 
3-hydroxypropyl-TPP also significantly reduced the RCR, but only at a concentration of 10 µM 
(4.33 ± 0.03; p-value <0.05, one-way ANOVA with Tukey’s HSD post-hoc test).  
To avoid possible overestimation bias that is inherently associated with statistical 
analysis of RCRs, values were mathematically converted to the related linear function termed 
“oxidative phosphorylation coupling efficiency”, where a value of 1.0 represents a perfectly 
coupled system (Gnaiger, 2014; Fig. 3.4B). The oxidative phosphorylation coupling efficiency in 
the presence of the vehicle control was 0.82 ± 0.01, compared to 0.72 ± 0.02 and 0.61 ± 0.02 for 
5 µM and 10 µM TPP-IOA, respectively (p-value < 0.05 for both doses compared to vehicle 
control, one-way ANOVA with Tukey’s HSD post-hoc test). The oxidative phosphorylation 
coupling efficiency was also significantly reduced by 10 µM 3-hydroxypropyl-TPP (0.77 ± 0.0; 
p-value < 0.05 compared to vehicle control, one-way ANOVA with Tukey’s HSD post-hoc test). 
Thus, through either metric it can be concluded that TPP-IOA significantly decreases the 
efficiency of oxidative phosphorylation in isolated mitochondria, and that its free mitochondria-
targeting chemical moiety 3-hydroxypropyl-TPP can also elicit this response at higher 
concentrations. The larger absolute changes observed for TPP-IOA compared to 3-
hydroxypropyl-TPP at lower doses suggests that the IOA moiety is required to decrease the 
coupling efficiency of mitochondria exposed to TPP-IOA, and that this moiety may be 
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negatively interacting with some functional component(s) of oxidative phosphorylation to drive 
the dysfunction. Additionally, at higher concentrations there may be a potentially minor 
contribution from the mitochondria-targeting moiety.  
To elucidate the functional processes of oxidative phosphorylation affected by TPP-IOA 
that contribute to the limited respiratory control/oxidative phosphorylation coupling of 
mitochondria, mitochondrial respiratory states defined by Chance and Williams (1955) were 
assessed. State 3 respiration represents capacity for phosphorylating respiration (saturating levels 
of exogenous substrates and ADP provided), and encompasses components of both the 
phosphorylating system and electron transport system. If TPP-IOA interferes with any 
component of these two systems, then a reduction in the State 3 respiration rate would be 
observed. State 3 respiration was decreased by TPP-IOA, with significant reductions compared 
to the vehicle control observed at both 5 µM and 10 µM (16.32 ± 2.24, 12.39 ± 1.27, and 9.18 ± 
1.33 nmol O2 consumed · min
-1
· mg protein
-1
, respectively; p-values < 0.05 for both doses, one-
way ANOVA with Tukey’s HSD post-hoc test; Fig. 3.4C). Respiration rates in response to 5 µM 
and 10 µM TPP-IOA were approximately 76 ± 7.79 % and 56 ± 8.16 % that of the vehicle 
control, respectively. Therefore, TPP-IOA can reduce the capacity for phosphorylating 
respiration by disrupting some functional component of the phosphorylating system or electron 
transport system. In contrast, similar concentrations of 3-hydroxypropyl-TPP did not alter State 3 
respiration, indicating that the free TPP-moiety does not contribute to the observed effects on 
oxidative phosphorylation. 
The rates of fully uncoupled respiration were also measured in the presence of the 
protonophore FCCP and absence of any ADP to allow for maximal electron transport activity 
with an inactive phosphorylation system (Fig. 3.4D). If TPP-IOA perturbs any functional 
component(s) of the mitochondrial electron transport system, then the capacity for fully 
uncoupled respiration would be lessened. The mean fully uncoupled respiration rate in the 
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presence of the vehicle control was 24.33 ± 2.57 nmol O2 consumed · min
-1
· mg protein
-1
. At 5 
µM and 10 µM TPP-IOA fully uncoupled respiration rates were significantly decreased (16.22 ± 
5.67 nmol O2 consumed · min
-1
· mg protein
-1
, or 66 ± 23.3 % and 16.42 ± 2.57 nmol O2 
consumed · min
-1
· mg protein
-1
, or 67 ± 10.56 % that of the vehicle control, respectively). 
Therefore, at concentrations of 5 µM and above, TPP-IOA interferes with the electron transport 
system of isolated mitochondria. In contrast, FCCP-uncoupled respiration was not affected by 3-
hydroxypropyl-TPP (p-value > 0.05 for all doses tested, one-way ANOVA with Tukey’s HSD 
post-hoc test).  
State 4 respiration is a measure of oxygen consumption not coupled to ADP 
phosphorylation, and is generally affected by processes that may stimulate the flow of protons 
from the intermembrane space back into the matrix independent of the ATP synthase (e.g. proton 
leak). If TPP-IOA exerts an effect on proton leak, then an increase in State 4/non-
phosphorylating respiration rate would be observed. Indeed, there was a general trend of 
increased State 4 respiration in the presence of TPP-IOA, with statistical significance observed at 
10 µM compared to the vehicle control (4.08 ± 0.52 nmol O2 consumed · min
-1
· mg protein
-1
 and 
2.79 ± 0.19 nmol O2 consumed · min
-1
· mg protein
-1
, respectively; p-value < 0.05, one-way 
ANOVA with Tukey’s HSD post-hoc test; Fig. 3.4E). Therefore, TPP-IOA significantly 
stimulates non-phosphorylating respiration, but only at relatively high concentrations. 
Additionally, 3-hydroxypropyl-TPP caused a general trend of elevated State 4 respiration rates 
(e.g. 3.37 ± 0.37 nmol O2 consumed · min
-1
· mg protein
-1
 at 10 µM TPP-OA versus 2.79 ± 0.19 
nmol O2 consumed · min
-1
· mg protein
-1
 for the vehicle group), however, this did not reach 
statistical significance (p-value > 0.05 versus the vehicle, one-way ANOVA with Tukey’s HSD 
post-hoc test).  
Taken together, these findings reveal that, at concentrations of 5 µM and greater, TPP-
IOA causes mitochondrial bioenergetic dysfunction, through interference with some 
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component(s) of the oxidative phosphorylation/electron transport system machinery and 
stimulation of some leak-inducing process(es). Both effects appear to require the IOA moiety of 
TPP-IOA, since the effects of the endogenously freed mitochondria targeting TPP-containing 
moiety manifest only at the highest concentrations tested, and even then with lower severity.  
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Figure 3.4: Inhibitory effects of TPP-IOA and its TPP-containing moiety on respiration of 
isolated mitochondria.   
A) Respiratory control ratio (RCR; State 3/State 4). B) Oxidative phosphorylation coupling 
efficiency (1 – RCR-1). C) State 3 respiration, or oxidative phosphorylation capacity (250 µM 
ADP addition). D) Fully uncoupled respiration, or electron transport system capacity (2 µM 
FCCP). E) State 4 respiration, or non-phosphorylating respiration. In A – E, measurements were 
made using isolated rat liver mitochondria provided with glutamate and malate (5 mM each) as 
respiratory substrate within a closed-chamber containing a Clark-type electrode. Blue 
diagonally-striped bars represent TPP-IOA treatment and red horizontally-striped bars represent 
3HP-TPP treatment. All bars represent means + SEM from at least three independent 
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mitochondrial preparations each measured in at least duplicate. * = p-value < 0.05, ** = p-value 
< 0.01, *** = p-value < 0.001 compared to Vehicle control (one-way ANOVA with Tukey’s 
HSD post-hoc test). 
 
 
 
 
 
3.5 Therapeutic efficacy of TPP-IOA at the level of isolated mitochondria: 
 Since TPP-IOA could directly cause dysfunction to components of oxidative 
phosphorylation in isolated mitochondria, it is crucial to determine whether it can exert desired 
inhibition to pro-apoptotic oxidative events at concentrations that avoid such toxicity. To identify 
this, the dose-responses for inhibition by TPP-IOA to both peroxidase activity and oxidative 
phosphorylation function (via measures of both RCR and oxidative phosphorylation coupling 
efficiency) of isolated mitochondria were plotted together (Fig. 3.5). Generally, concentrations 
of TPP-IOA required for appreciable inhibition of peroxidase activity elicited an even stronger 
reduction to the RCR (Fig. 3.5A,C). Additionally, the oxidative phosphorylation coupling 
efficiency appears to have been concomitantly inhibited with peroxidase activity over the 
concentration range of TPP-IOA tested (Fig. 3.5B,D). Together, these measures indicate that 
TPP-IOA is unable to inhibit peroxidase activity without concomitantly disrupting oxidative 
phosphorylation of mitochondria. 
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Figure 3.5: Merged dose-response relationships for TPP-IOA’s inhibitory effects on 
peroxidase activity and respiration of isolated mitochondria.  
A,B) Non-transformed and C,D) semi-log transformed dose-response curves for TPP-IOA’s 
inhibition of both peroxidase activity and either respiratory control or oxidative phosphorylation 
coupling of isolated mitochondria. Solid red boxes represent means ± SEM of peroxidase 
activity, whereas solid blue dots represent respiratory control ratio (RCR) in (A,C) and oxidative 
phosphorylation efficiency in (B,D) of isolated rat liver mitochondria. Data points represent 
means ± SEM from three (RCR and oxidative phosphorylation efficiency) or four (peroxidase 
activity) independent mitochondrial preparations each measured in at least duplicate. Data points 
in each data set were derived from data shown in Fig. 3.1D and Fig. 3.4A,B and were 
standardized to respective vehicle (0.1% DMSO) control values. 
 
 
 
3.6 Impact of TPP-IOA on mitochondrial bioenergetics in intact cultured cells: 
Although the cell-free experimental approach provides useful insights into TPP-IOA’s 
interactions with basic molecular or biochemical processes underlying cell function(s) of interest, 
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it has translational limitations owing to the absence of a fully physiological intracellular 
environment. Therefore, additional investigations were conducted in live cultured cells.  
It was hypothesized that changes in bioenergetic parameters observed in isolated 
mitochondria would be evident also in intact cells exposed to TPP-IOA. To address this 
hypothesis, mitochondrial membrane potential and respiration rates, indicative of mitochondrial 
proton motive force and proton current, respectively, were assessed in cultured SH-SY5Y human 
neuroblastoma cells. Mitochondrial membrane potential is the major component of the proton 
motive force that drives ATP production from oxidative phosphorylation. This was semi-
quantitatively assessed in SH-SY5Y-mito-mEFP cells using confocal fluorescence imaging with 
the lipophilic membrane-permeant red fluorescent cation TMRM (Fig. 3.6), whose 
mitochondrial uptake is proportional to membrane potential (Scadutto Jr. and Grotyohann, 1999). 
TMRM was used in non-quench mode whereby a decrease in mitochondrial membrane potential 
corresponds to decreased TMRM fluorescence intensity (Nicholls, 2012, Perry et al., 2011). 
FCCP treatment was used as a control to confirm that TMRM fluorescence intensity decreased 
when the mitochondrial membrane potential was dissipated (personal observations from 
preliminary assay optimization experiments; data not shown). In SH-SY5Y cells exposed to 
TPP-IOA (1 µM), mitochondrial TMRM fluorescence intensity was decreased compared to that 
of vehicle control-treated cells (37155 ± 3514 arbitrary fluorescence units per cell versus 54421 
± 2608 arbitrary fluorescence units per cell, respectively; p-value < 0.001, Student’s t-test; Fig. 
3.6A middle panel for representative images depicting TMRM fluorescence signal,  and Fig. 
3.6B for TMRM fluorescence signal quantification), indicating TPP-IOA can dissipate the 
mitochondrial membrane potential in intact cells. 
Oxygen consumption rates (nmol O2 consumed · min
-1
) of intact SH-SY5Y human 
neuroblastoma cells were measured using closed-system respirometry (Fig. 3.7), and were 
initially standardized to cell number (Fig. 3.7A).  The basal oxygen consumption rate of intact 
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cells acutely exposed to TPP-IOA (1 µM; 3 hours) remained unchanged compared to that of 
vehicle control-treated cells (1.46 ± 0.06 nmol O2 consumed · min
-1
 · million cells
-1 
versus 1.47 ± 
0.33 nmol O2 consumed · min
-1
 · million cells
-1
, respectively; p-value < 0.05), suggesting that 
TPP-IOA does not exert a detectable effect on any processes that exert major control over the 
basal respiration rate.  
The protonophore FCCP was subsequently used to chemically uncouple oxygen 
consumption from ATP synthesis, thereby allowing for fully uncoupled respiration rates and an 
indication of potential impairments to functional components of the electron transport system. 
Expectedly, both vehicle-treated and TPP-IOA (1 µM)-treated cells exhibited significantly 
elevated fully uncoupled respiration rates compared to their respective basal respiration rates (p-
values < 0.05 and < 0.001 compared to basal rates for DMSO and TPP-IOA groups, respectively; 
Student’s t-test). However, the fully uncoupled respiration rate was significantly attenuated in the 
presence of TPP-IOA compared to the vehicle-treated cells (2.06 ± 0.02 nmol O2 consumed · 
min
-1
 · million cells
-1
 versus 2.66 ± 0.33 nmol O2 consumed · min
-1
 · million cells
-1
; p-value < 
0.05, Student’s t-test), suggesting that TPP-IOA decreases the aerobic capacity of SH-SY5Y 
cells.  
Respiration rates standardized to cell number do not take into account any changes in the 
abundance of mitochondria that may underlie experimental trends, such as in the results above. It 
was later determined that TPP-IOA (1 µM for 3hrs) elicited changes consistent with reduced 
mitochondrial abundance (see section 3.7 below for this data). Therefore, to account for 
differences in mitochondrial content between treatment groups at the time of respiration 
measurements, all oxygen consumption rates (nmol O2 consumed · min
-1
) were also standardized 
to
 
activity of citrate synthase (e.g. as in Picard et al., 2008; Fig. 3.7B), a mitochondrial matrix 
enzyme whose expression level and maximal activity correlate strongly with mitochondrial 
content (Larsen et al., 2012).  
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Compared to the vehicle control, TPP-IOA caused elevated basal oxygen consumption 
rates per unit citrate synthase (0.03622 ± 0.00391 nmol O2 · min
-1
 · unit citrate synthase
-1
, versus 
0.0503 ± 0.0057 nmol O2 consumed · min
-1
 · unit citrate synthase
-1
 respectively; p-value 0.06, 
Student’s t-test). As expected, respiration rates standardized to citrate synthase activity were 
elevated in the fully uncoupled state (FCCP addition) compared to the basal state of cells 
receiving the vehicle control (0.0533 ± 0.00698 nmol O2 consumed · min
-1
 · unit citrate synthase
-
1
 versus 0.03622 ± 0.00391 nmol O2 · min
-1
 · unit citrate synthase
-1
, respectively; p-value < 0.05, 
Student’s t-test). In contrast, fully uncoupled oxygen consumption rates per unit citrate synthase 
in TPP-IOA treated-cells were not significantly increased compared to under the basal state 
(0.05301 ± 0.01354 nmol O2 consumed · min
-1
 · unit citrate synthase
-1 
versus 0.0503 ± 0.00573 
nmol O2 consumed · min
-1
 · unit citrate synthase
-1
, respectively). Therefore, while basal 
respiration rates standardized to cell number were unchanged in response to TPP-IOA, rates of 
basal respiration standardized to a proxy for mitochondrial content were elevated from the 
control treatment to near the uncoupled rates. Together, these findings indicate that TPP-IOA 
influences some component(s) of cellular or mitochondrial bioenergetics in intact cells that 
exerts control over the basal oxygen consumption rate.  
Additionally, fully uncoupled oxygen consumption rates per unit citrate synthase did not 
differ between vehicle control and TPP-IOA groups (0.05301 ± 0.01354 nmol O2 consumed · 
min
-1
 · unit citrate synthase
-1 
and 0.05331 ± 0.00698 nmol O2 consumed · min
-1
 · unit citrate 
synthase
-1
, respectively; p-value 0.9837, Student’s t-test), suggesting that by this measure TPP-
IOA does not significantly interfere with component(s) affecting proton current capacity (e.g. 
respiratory chain activity of the electron transport system). 
 Taken together with the above respirometry findings, it can be concluded that TPP-IOA 
impacts mitochondrial bioenergetics within intact cells by depolarizing the mitochondrial 
membrane potential and stimulating respiration. This, together with the shared similarity to the 
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responses to FCCP, are consistent with a possible mitochondrial uncoupling effect by TPP-IOA 
in live cells.  
 
 
 
Figure 3.6: TPP-IOA dissipates mitochondrial membrane potential in intact SH-SY5Y 
human neuroblastoma cells. 
A) Representative fluorescence images of TMRM-stained (40 nM; non-quench mode) single SH-
SY5Y-mito-mEFP cells at 30 minutes of exposure to DMSO (top) or 1 µM TPP-IOA (bottom). 
Left panel: mito-mEFP signal (green; visual reference for mitochondrial location). Middle 
panel: membrane potential-dependent TMRM signal (red). Right panel: Overlay of mEFP and 
TMRM fluorescence signals. B) TMRM fluorescence signal intensity per cell is lowered in 
response to 1 µM TPP-IOA. Bars represent means + SEM of 12 cells per group from two 
independent experiments. *** = p-value < 0.001 (Student’s t-test).  
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Figure 3.7: TPP-IOA interferes with cellular respiration in intact SH-SY5Y cells.  
A) Basal and FCCP-uncoupled (2 µM FCCP addition) respiration rates (nmol O2 consumed per 
minute) standardized to cell count (per million cells). B) Basal and FCCP-uncoupled (2 µM 
FCCP addition) respiration rates standardized to mitochondrial content (nmol O2 consumed per 
minute per unit citrate synthase). SH-SY5Y cells cultured in glucose-containing DMEM were 
harvested for measurements at 3 hours of exposure to 1 µM TPP-IOA or an equivalent amount of 
DMSO (0.1%; vehicle control). Bars represent means + SEM from either two or three 
independent experimental replicates. * = p-value < 0.05, # = p-value < 0.06, *** = p-value < 
0.001 (unpaired Student’s t-test). 
 
 
 
 
 
3.7 Impact of TPP-IOA on mitochondrial dynamics in intact cultured cells: 
  
Components of mitochondrial dynamics, including morphology of the mitochondrial 
network and intracellular abundance of mitochondria, are intimately associated with 
bioenergetics. Generally, a fused and interconnected mitochondrial network is associated with 
increased bioenergetic efficiency (i.e. O2 consumption strongly coupled to ATP synthesis), 
whereas the opposite has been reported for a fragmented network containing more punctate 
mitochondria. Since TPP-IOA disrupted mitochondrial membrane potential, it was predicted that 
TPP-IOA would also promote fragmentation of the mitochondrial network. To address this, 
confocal microscopy was used to image SH-SY5Y-mito-mEFP cells (Fig. 3.8). In these cells, a 
less interconnected, more fragmented mitochondrial network, was visually apparent at 3 hours of 
TPP-IOA (1 µM) exposure compared to control cells (Fig. 3.8A). These morphological changes 
70 
 
were evident as early as 45 minutes following TPP-IOA addition to media and were fully 
manifested by approximately 90 minutes (personal observations). A similar morphological 
change was also observed in C2C12 mouse myoblasts and SH-SY5Y cells not expressing mito-
mEFP but labelled with MitoTracker Red CMXRosamine dye (see Appendix I Fig. AI.5.2 and 
Fig. AI.5.3). These observations indicate that the fragmentation effect of TPP-IOA on the 
mitochondrial network is neither specific to SH-SY5Y cells, nor artifactually mediated by the 
mitochondrial labelling technique used. Additionally, FCCP was included as a positive control 
for the fragmentation response to chemical uncoupling of oxidative phosphorylation. FCCP (1 
µM)-treated cells also contained an extensively fragmented mitochondrial network (Fig. 3.8A). 
Thus, changes to mitochondrial network morphology caused by TPP-IOA (1 µM) appear to be 
generally similar to those caused by a known chemical uncoupler of oxidative phosphorylation. 
Additionally, the morphological changes to the mitochondrial networks within the SH-
SY5Y-mito-mEFP cells were quantitatively analyzed using the custom-developed 
“Mitochondrial Analysis V1.0.0” ImageJ tool (Valente, unpublished – see Appendix II for 
detailed description). Both the number of mitochondrial networks (i.e. mitochondrial structures 
with at least one branching point) per cell and mean number of branches per mitochondrial 
network were quantified from the skeletonized depiction of mitochondrial signal (see both 
middle and top panels of Fig. 3.8A). TPP-IOA (1 µM) significantly increased the number of 
individual mitochondrial networks in cells (14.67 ± 1.42 mitochondrial networks per cell versus 
9.07 ± 1.38 mitochondrial networks per cell in DMSO-treated cells; p-value < 0.05; one-way 
ANOVA with Tukey’s HSD post-hoc test). This was similar to the response to FCCP (19.13 ± 
1.42 mitochondrial networks per cell; p-value < 0.001 compared to DMSO cells; one-way 
ANOVA with Tukey’s HSD post-hoc test). Additionally, there was a significantly lesser mean 
number of branches per mitochondrial network in response to TPP-IOA (11.07 ± 0.87) than in 
control cells (25.98 ± 3.16; p-value < 0.001, one-way ANOVA with Tukey’s HSD post-hoc test). 
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This too was similar to the response to FCCP (7.26 ± 0.41; p-value < 0.001 compared to control, 
one-way ANOVA with Tukey’s HSD post-hoc test). Altogether, the quantitative analysis 
indicates that TPP-IOA can cause mitochondrial networks to fragment into a greater number of 
individual networks with less extensive branching. This fragmentation response is similar to that 
caused by a potent chemical uncoupler. This fact, combined with the observed changes to 
energetics (section 3.6 above), further suggests that TPP-IOA can act as an uncoupler of 
oxidative phosphorylation in live cells. 
Mitochondria with disrupted bioenergetics (e.g. possessing a sufficiently decreased 
membrane potential) can be selectively removed and degraded through mitophagy. Such 
degradation has been observed in cultured cells exposed to chemical disruptors of oxidative 
phosphorylation (e.g. McLelland et al., 2014). Since TPP-IOA caused both a disrupted 
mitochondrial membrane potential and a fragmented mitochondrial network in cells, it was 
hypothesized that TPP-IOA could be a stimulator of mitophagy. Since mitophagy can be 
reflected as a loss of apparent mitochondrial content in cells (e.g. Dolman et al., 2013, Ding and 
Yin, 2012), a reduction in mitochondrial content was predicted to occur following TPP-IOA 
treatment if mitophagy had occurred. To address this, two mitochondrial-specific content 
markers - maximal activity of the TCA cycle enzyme citrate synthase and the protein level of 
outer mitochondrial membrane protein voltage-dependent anion channel (VDAC) - were 
measured in whole-cell lysates of SH-SY5Y cells harvested 3 hours following the addition of 
TPP-IOA (1 µM) treatment (Fig. 3.9). Maximal citrate synthase activity levels were significantly 
lower in lysates of TPP-IOA-treated cells than of vehicle-control treated cells (184.8 ± 16.55 
nmol TNB formed · min
-1
 · mg cellular protein
-1
 versus 268.5 ± 12.18 nmol TNB formed · min
-1
 
· mg cellular protein
-1
 in vehicle control cells; p-value 0.0164, Student’s t-test; Fig. 3.9A). 
Additionally, VDAC protein expression levels were significantly lower in lysates from TPP-
IOA-treated cells compared to vehicle control cells, as determined by immunoblot (relative 
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protein band densities of 0.736 ± 0.0050 and 0.91 ± 0.0900, respectively; p-value 0.0408, 
Student’s t-test; Fig. 3.9B). Together, these two measures indicate that TPP-IOA stimulated a 
reduction in mitochondrial content in cultured cells.  
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Figure 3.8: TPP-IOA alters mitochondrial network morphology in intact SH-SY5Y cells. 
A) TPP-IOA (1µM) causes fragmentation of mitochondria in SH-SY5Y-mito-mEFP cells, but to 
an apparent lesser degree than FCCP (1µM). Top panel: Raw confocal images of SH-SY5Y-
mito-mEFP cells at 3hrs of indicated treatment (1 µM or equivalent volume of DMSO. Images 
were acquired using a Zeiss Axio Observer.Z1 inverted epifluorescence microscope (ex. 488 nm, 
em. 509 nm) equipped with ApoTome.2 optical sectioning, a 63x oil objective, and Hamamatsu 
camera, and are maximum intensity projections of z-stack series (≥ 25 slices, 0.25 – 0.30 µm 
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apart). Middle panel: Corresponding skeletonized depiction of mito-mEGP signal, as generated 
by post-acquisition processing with the “Mitochondrial Network Analysis, V1.0.1” ImageJ 
macro. Bottom panel: Overlay of the processed mito-mEFP signal with the skeleton depiction. 
B) TPP-IOA and FCCP (1µM each) increase the mean number of mitochondrial networks per 
cell. C) TPP-IOA and FCCP (1µM each) increase the mean number of branches per 
mitochondrial network. In (B) and (C), measures were obtained from the “Mitochondrial 
Network Analysis, V1.0.1” ImageJ macro. Bars represent means + SEM from 15 total individual 
cells from two independent experiments. * = p-value < 0.05, *** = p-value < 0.001 compared to 
vehicle control (one-way ANOVA with Tukey’s HSD post-hoc test).  
 
 
 
 
 
 
Figure 3.9: TPP-IOA reduces mitochondrial content in SH-SY5Y cells.  
A) TPP-IOA (1µM) decreases maximal citrate synthase activity (nanomol TNB formed·min
-
1
·milligram cellular protein
-1
). B) TPP-IOA (1µM) decreases VDAC protein levels (expression 
relative to an internal standard). Top inset depicts representative VDAC (~32 kDa) and β-actin 
(~43 kDa; probed as a loading control) immunoblot bands of indicated sample proteins separated 
by SDS-PAGE. In both figures, measurements were made with whole-cell lysates prepared from 
SH-SY5Y cells cultured in glucose-containing medium and harvested immediately after 3 hours 
of exposure to 0.1% DMSO (Vehicle control) or 1 µM TPP-IOA. Bars represent means + SEM 
from two or three experimental replicates. * = p-value < 0.05 (unpaired Student’s t-test). 
 
 
 
 
VDAC 
Actin 
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3.8 Influence of oxidative phosphorylation dependency on TPP-IOA’s protective efficacy in 
intact cultured cells 
Having observed changes that are associated with reduced mitochondrial ATP output in 
cells, as well as a narrow-to-non-existent therapeutic window between peroxidase inhibition and 
oxidative phosphorylation coupling measures with isolated mitochondria, it was hypothesized 
that TPP-IOA’s protective capability in cells would be influenced by the relative reliance on 
oxidative phosphorylation. To investigate this, SH-SY5Y cells were cultured in either a glucose-
free/galactose-&glutamine-containing medium (hereafter ‘galactose medium’) to promote 
reliance on oxidative phosphorylation, or a glucose-containing medium that preferentially allows 
for ATP generation via glycolysis (Reitzer et al., 1979, & Rossignol et al., 2004; Gusdon et al., 
2012). The metabolic adaptation of SH-SY5Y cells to a galactose medium results in higher 
oxygen consumption rates and increased sensitivity to impaired ATP output from impaired 
mitochondrial energetics (Gusdon et al., 2012, Swerdlow et al., 2013). Consistent with these 
previous studies, SH-SY5Y cells cultured here in a galactose medium exhibited a significant 
increase in basal respiration rate compared to cells cultured in a glucose-containing medium 
(Fig. 3.10; 4.463 ± 0.5036 nmol O2 · min
-1
 · million cells
-1
 versus 1.473 ± 0.3263 nmol O2 · min
-
1
 · million cells
-1
, respectively; p-value 0.0038, Student’s t-test).  
To assess TPP-IOA’s anti-apoptotic effectiveness under each culture condition, the 
oxidant H2O2, which is a robust stimulator of the mitochondrial pathway of apoptosis (e.g. Singh 
et al., 2007), was used at doses that evoked approximately 50% cell loss (Fig. 3.11). In SH-
SY5Y cells cultured in glucose-containing media, 300 µM H2O2 evoked 45.6 ± 1.9 % cell loss 
after 24 hours, as determined from cell viability counts using a Trypan blue exclusion assay 
(corresponding to 54.4 ± 1.9% total viability; Fig. 3.11A). In the presence of a wide range of 
TPP-IOA concentrations, (0.25 – 2.5 µM), the extent of total cell death was significantly reduced 
compared to non-treated controls (Fig. 3.11A). This improvement in cell viability was not 
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observed at higher concentrations of TPP-IOA, as 5 µM and 10 µM failed to exert a protective 
effect (see Appendix I Fig. AI.5.4). Furthermore, liberated AMC fluorescence resulting from 
characteristic cleavage of the peptide substrate Ac-DEVD-AMC by active Caspase-3 (Talanian 
et al., 1997) was used as a proxy for Caspase-3 activity in cell lysates and a marker for apoptosis. 
AMC fluorescence was elevated 3.26 ± 0.43-fold in response to 300 µM H2O2 exposure (Fig. 
3.12A), thus indicating active Caspase-3 activity and involvement of apoptotic cell death under 
these lethal conditions. The induction of Caspase-3 activity was also lowered by TPP-IOA over a 
similar concentration range compared to non-treated controls, with statistically significant 
inhibition at 1 µM (Fig. 3.12A). Additionally, TPP-IOA (at 1 µM and 2.5 µM, but not at either 5 
µM or 10 µM) limited H2O2-induced cell loss in C2C12 murine myoblasts cultured in a similar 
glucose medium, suggesting that its protective effect is not cell-type specific (see Appendix I 
Fig. AI.5.5). Altogether, these results indicate that TPP-IOA can prevent total cell death by 
inhibiting apoptosis in cells that are glycolytic and relatively less aerobic. 
When grown in galactose medium, SH-SY5Y cells were generally more sensitive to 
H2O2, as 45.6± 1.929 % cell loss was evoked by only 200 µM H2O2 (corresponding to 53.41 ± 
2.95 % total viability; Fig. 3.11B). At this concentration, Caspase-3 activity was similarly 
elevated compared to non-treated controls (3.39 ± 0.44 -fold increase; Fig. 3.12B). However, 
TPP-IOA (tested as low as 0.25 µM and up to 5 µM) failed to significantly prevent cell death or 
Caspase-3 activation in comparison to non-treated control groups under the same culture 
conditions (Fig. 3.11A and Fig. 3.12B). Together with the above findings, these results indicate 
that TPP-IOA can exert anti-apoptotic effects in cultured cells that utilize primarily glucose 
fermentation, but not in cells that are reliant on oxidative phosphorylation. Therefore, a lack of 
cellular dependence on oxidative phosphorylation is an important factor contributing to TPP-
IOA’s anti-apoptotic/cytoprotective effectiveness in cells. 
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Figure 3.10: Replacing glucose-containing culture medium with glucose-free/galactose-
containing culture medium enhances the basal oxygen consumption rate of SH-SY5Y 
human neuroblastoma cells.  
Measurements of cells in glucose-free/galactose-containing culture media were performed five 
days after switching from glucose-containing culture media. Bars represent means + SEM from 
three individual replicates per condition. ** = p-value < 0.01 (one-tailed Student’s t-test). 
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Figure 3.11: TPP-IOA inhibits H2O2-induced total death in SH-SY5Y cells allowed to 
ferment glucose but not in cells reliant on mitochondrial oxidative phosphorylation for 
ATP production.  
A) TPP-IOA reduces the amount of total cell death caused by H2O2 in SH-SY5Y cells cultured in 
high glucose-containing media. Bars represent means + SEM from 7 – 14 total replicates from 3 
– 5 independent experiments. ** = p-value < 0.01, *** = p-value < 0.001 compared to H2O2 
control (black bar; one-way ANOVA with Tukey’s HSD post-hoc test). B) TPP-IOA does not 
protect against cell death caused by H2O2 in SH-SY5Y cells cultured in glucose-free/galactose-
containing media. Bars represent means + SEM from 6 – 11 total replicates from 3 – 5 
independent experiments. No significant differences between H2O2-treated groups were observed 
(one-way ANOVA). Total cell death was assessed using the Trypan blue exclusion assay. All 
data were standardized to untreated-treated controls (white bar). TPP-IOA (blue diagonally-
striped bars) was administered at the same time as H2O2. Doses of H2O2 previously determined 
to cause approximately 50% total cell death under each culture regime were used (300 µM in (A) 
and 200 µM in (B); dose-response data not shown). 
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Figure 3.12: TPP-IOA prevents induction of Caspase-3 activity by H2O2 exposure in SH-
SY5Y cells allowed to ferment glucose but not in cells that are reliant on mitochondrial 
oxidative phosphorylation.  
A) TPP-IOA suppresses H2O2-induced Caspase-3 activation in SH-SY5Y cells cultured in high 
glucose-containing media. Bars represent means + SEM from 5 – 7 total replicates from 3 – 5 
independent experiments. * = p-value < 0.05 compared to H2O2 control (black bar; one-way 
ANOVA with Tukey’s HSD post-hoc test). B) TPP-IOA does not prevent H2O2-induced 
Caspase-3 activation in SH-SY5Y cells cultured in glucose-free/galactose-containing media. 
Bars represent means + SEM from 5 – 7 total replicates from 3 – 4 independent experiments. No 
significant differences between H2O2-treated groups were observed (p-value > 0.05, one-way 
ANOVA). All data were standardized to untreated-treated controls. TPP-IOA (blue diagonally-
striped bars) was administered at the same time as H2O2. Caspase-3 activity [AMC fluorescence 
intensity (ex. 360 nm, em. 445 nm) per 25 µg cellular protein] were measured in cell lysates 
prepared from cells harvested immediately at 12 hours from the onset of 200 μM (B) or 300 μM 
(A) H2O2 exposure. 
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Chapter 4.0 – Discussion: 
 
4.1 Effects of TPP-IOA on the reduction of purified cytochrome c: 
Prior to the current study, TPP-IOA’s effect on cytochrome c’s respiration-associated 
electron transfer activity had not been investigated. Here, it was discovered that TPP-IOA can 
inhibit reduction of cytochrome c’s heme iron, which is essential for electron chain activity 
during oxidative phosphorylation. Since the imidazole group of TPP-IOA acts as a ligand for the 
heme iron (Atkinson et al., 2011), it is possible that this is a direct effect of the imidazole group. 
Consistent with this notion is the fact that exogenously added imidazole can also inhibit 
cytochrome c reduction by replacing the iron-binding sulphur of the native Met80 ligand in 
cytochrome c (Babul & Stellwagen, 1971; Schejter & Aviram, 1969). However, the observation 
that TPP-oleic acid, which is devoid of an imidazole ligand, also slowed cytochrome c reduction 
kinetics suggests that the disruptive effect of TPP-IOA may have been caused by a different 
interaction.  
It has been shown that binding of oleic acid to cytochrome c can cause conformational 
changes or partial unfolding of the protein that includes a weakening or loss of native Met80-
heme iron coordination (Stewart et al., 2000, Sinibaldi et al., 2005, Patriarca et al., 2009). Such 
disruptions to the heme environment appear to have been reported at concentration ratios as low 
as 1:2 oleate to cytochrome c (Stewart et al., 2000), which is smaller than the ratio at which TPP-
oleic acid caused major disruption to cytochrome c’s reduction activity here.  This, coupled with 
the fact that the reduction activity of cytochrome c is sensitive to general structural/heme 
environment changes in the protein (Moore and Pettigrew, 1990), suggests that the disruption to 
cytochrome c’s reduction activity by TPP-IOA could be due to structural disruptions resulting 
from the oleate’s interaction with the protein.  
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4.2 Effects of TPP-IOA on isolated mitochondria: 
Much higher levels of TPP-IOA were required to achieve inhibition of peroxidase 
activity with isolated rat liver mitochondria (40 nmol TPP-IOA per mg mitochondrial protein) 
than with purified cytochrome c (0.5 nmol TPP-IOA per nmol cytochrome c; c.a. 1:1). Using the 
reported value of approximately 0.21 nmol cytochrome c per mg mitochondrial protein in adult 
rat liver (Wainio, 1970; Petrosillo et al., 2003), it can be estimated that approximately 190-fold 
higher ratio of TPP-IOA:cytochrome c was required to achieve 50% reduction of its peroxidase 
activity in isolated mitochondria. This requirement for an excessive amount of TPP-IOA may be 
reconciled by the fact that there are greater molecular barriers to TPP-IOA’s interaction with 
cytochrome c, which is located within the inter-membrane space (e.g. Scoranno et al., 2002).    
Although much higher concentrations of TPP-IOA were required, it nonetheless had 
significant effects on respiratory control and oxidative phosphorylation coupling efficiency in 
isolated mitochondria at concentrations similar to those needed to inhibit cytochrome c’s 
peroxidase activity. TPP-IOA adversely affects some functional component(s) of both the 
phosphorylating system, which may include ATP synthase, ANT, and/or the phosphate carrier, 
the electron transport system and/or substrate transporters. The elevated State 4 respiration rates 
in the absence of State 3 stimulation suggest that TPP-IOA stimulates proton leak. This could be 
due to direct effects on the phospholipid bilayer, or effects on membrane protein-mediated 
activities (e.g. uncoupling proteins), or a combination of both. The data do not allow for 
discernment between the two possibilities. 
It is possible that the effects of TPP-IOA on oxidative phosphorylation are mediated 
partly by the long chain fatty acid structure. Long chain fatty acids have been shown to affect 
mitochondrial respiratory states in much the same manner as TPP-IOA (i.e. elevated State 4/non-
phosphorylating respiration rates, and decreased State 3 and fully uncoupled respiration rates in 
isolated mitochondria; e.g. see citations in Wojtczak, 1976, Wojtczak & Schönfeld, 1993, and Di 
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Paola and Lorusso, 2006). There is evidence for interactions of long chain fatty acids with some 
transporter proteins of the phosphorylation and electron transport systems, including ANT 
(Wojtczak & Zaluska, 1967; Andreyev et al., 1989), phosphate carrier (Záková et al., 2000, 
Engstová et al., 2001), aspartate/glutamate antiporter (Samartsev et al., 1997), and the 
dicarboxylate carrier (Wieckowski et al., 1997). These various substrate transporters have been 
reported to mediate the uncoupling and/or protonophoric activity of long chain fatty acids, and 
the interactions could also perturb their proper functioning and lead to impaired State 3 and/or 
fully uncoupled respiration. Similar interactions between these transporter proteins and the long 
chain fatty acid moiety of TPP-IOA may be possible, the functional outcome of which would be 
consistent with the perturbations to mitochondrial respiration elicited by TPP-IOA. 
The imidazole group on the acyl chain of TPP-IOA may also contribute to perturbations 
of oxidative phosphorylation. Molecules belonging to the imidazole class of antimycotics can 
cause uncoupling of oxidative phosphorylation and/or dissipation of membrane potential in 
isolated rat liver mitochondria and cultured mammalian cells (Kawahi et al., 1983; Andreux et 
al., 2014). A future comparison of the absolute rates of various mitochondrial respiratory states 
in the presence of TPP-IOA versus that in the presence of TPP-OA may directly clarify this. 
Whether perturbed mitochondrial respiration is a fundamental effect of imidazole fatty acid 
derivatives could be of importance to the development of imidazole-fatty acid molecules, 
particularly since a number of TPP-conjugated stearic acid derivatives with imidazole present at 
different parts of the acyl chain have already been synthesized and tested for their anti-apoptotic 
effectiveness (Jiang et al., 2014). Though the location of the imidazole group is reportedly 
important for the anti-apoptotic effectiveness of these molecules (Jiang et al., 2014), this may not 
matter for perturbations of oxidative phosphorylation.  
Others have reported that lipophilic TPP-containing linker moieties devoid of any active 
chemical group may not be bioenergetically inert and can interfere with mitochondrial energy 
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coupling processes (Reily et al., 2013; Trnka et al., 2015). In the current study, the decreased 
RCR and oxidative phosphorylation coupling efficiency of isolated rat liver mitochondria in the 
presence of 3-hydroxypropyl-TPP indicate that the free TPP-containing moiety also has the 
capacity to directly interfere with oxidative phosphorylation. That this effect was driven by 
elevated State 4/non-phosphorylating respiration is consistent with a prior published report 
showing increased oligomycin-insensitive (non-phosphorylating) respiration in intact cells 
exposed to other TPP-containing linker moieties (Trnka et al., 2015). Notably, in this prior study 
the uncoupling-like response occurred with alkyl-TPP linker molecules containing lengthy alkyl 
chains (e.g. decyl-TPP) but not shorter alkyl chains, such as propyl-TPP. The hydroxyl group 
present at the end of the propyl chain of 3-hydroxypropyl-TPP is likely to be a significant 
additional structural feature in conferring any direct uncoupling-like activity of this short alkyl-
chained TPP-containing molecule, as an acid-dissociable group is a crucial property allowing for 
a chemical uncoupler to mediate proton translocation (Terada, 1990).  
Aside from a direct disruptive effect, it is also possible that 3-hydroxypropyl-TPP could 
work in conjunction with the free imidazole-oleic acid to potentiate disruptive activity. In 
agreement with this, there is evidence that lipophilic cations, including TPP-derivatives, can 
potentiate the protonophoric uncoupling activity of exogenous long chain fatty acids and have 
been proposed to do so by pairing with the anionic form of the fatty acid to form an ion-pair 
complex to facilitate movement across the inner mitochondrial membrane from the matrix 
(Schönfeld, 1992; Severin et al., 2010; Trendeleva et al., 2012). Regardless of the exact 
mechanism underlying the dysfunction, the data obtained here using isolated rat liver 
mitochondria indicate that the TPP-containing moiety of TPP-IOA can impact mitochondrial 
bioenergetic function at sufficiently high concentrations by stimulating non-phosphorylating 
respiration. In general, these data highlight the importance of including an experimental control 
of the TPP-moiety alone when studying small molecules targeted to mitochondria via TPP-
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conjugation, particularly in the experimental context of bioenergetics as it is becoming 
increasingly evident that such molecules can impact energetic processes of mitochondria. 
 
4.3 Effects of TPP-IOA on cultured cells: 
In live cells, perturbed oxidative phosphorylation is associated with a more fragmented 
mitochondrial morphology. In this study, untreated SH-SY5Y cells contained mitochondrial 
networks with extensive branching, whereas cells treated with FCCP (positive control for 
fragmentation) featured more individual networks (i.e. network fragmentation) with less 
extensive branching. These findings are consistent with a recent study showing decreased 
network fiber lengths and networked area in response to uncoupling (CCCP), using a similar 
method for automated image processing (Leonard et al., 2015).  Changes to the mitochondrial 
network in response to TPP-IOA observed here were generally similar to those elicited by FCCP, 
though the response was less pronounced. This observation, in addition to the elevated rates of 
basal respiration and decreased mitochondrial membrane potential, indicate that TPP-IOA’s 
effects on mitochondria are consistent with uncoupling. Although the development of the 
processing/analysis macro was not a focal point of the current study, the experimental data 
obtained from it does serve as proof that it can be a useful quantitative diagnostic tool for 
identifying and describing mitochondrial network morphology changes. 
Decreased mitochondrial membrane potential, fragmentation of mitochondria, and 
decreased levels of mitochondrial content makers were all observed within 3h of 1 µM TPP-IOA 
introduction. Together, these changes suggest the induction of uncoupling-induced mitophagy 
(e.g. Ashrafi & Schwartz, 2013) by TPP-IOA. This could have important physiological 
implications for TPP-IOA’s anti-apoptotic activity, which revolves around the prevention of 
cytochrome c release into the cytosol.  Although not measured in the current study, a decrease in 
mitochondrial content via mitophagy results in less cytochrome c within the cell (Saita et al., 
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2013). With less total cytochrome c available for release, activation of Caspase-activating 
cascades and other downstream apoptotic cell death activities might be limited. Indeed, others 
have shown that enhanced activation of mitophagy suppresses cytochrome c release into the 
cytosol and inhibits apoptosis (Mariño et al., 2014; Xia et al., 2014; Choe et al., 2015). The 
decreased H2O2-induced Caspase-3 activity and total cell death elicited by TPP-IOA in glucose-
cultured SH-SY5Y cells (discussed further below) are consistent with such a mechanism of cell 
death protection. It is also possible for this mechanism to have at least partly been involved in the 
protection by TPP-IOA (at 2.5 µM and 5 µM) from radiation-induced death in cultured 
fibroblasts previously observed (Atkinson et al., 2011). Notably, this possibility cannot be ruled 
out from the data provided in that study, as none of the measures provided could serve as 
mitochondrial content markers. It is therefore possible that, in addition to direct physical 
inhibition of cytochrome c’s pro-apoptotic peroxidase activity, TPP-IOA’s anti-apoptotic 
mechanism of action could involve mitophagy induction secondary to the disruption of oxidative 
phosphorylation. 
Proliferative cells, including those in culture that are cancerous or transformed, often 
feature increased rates of glycolysis relative to oxidative phosphorylation (e.g. Lunt & Vander 
Heiden, 2011). As a consequence of meeting a greater proportion of ATP demand via glycolysis, 
such cells may be particularly tolerant of perturbations affecting oxidative phosphorylation. 
Since initial results indicated that TPP-IOA offered protection against cell death but also 
interfered with oxidative phosphorylation, it was important to study cells growing under 
conditions that increased reliance on oxidative phosphorylation. This was achieved by altering 
the carbohydrate source, either glucose or galactose, provided in the culture medium. SH-SY5Y 
cells cultured in a galactose medium had higher rates of oxygen consumption [Fig. 3.11], as 
expected (Swerdlow et al., 2013; Gusdon et al., 2012), indicating a greater reliance on oxidative 
phosphorylation (e.g. Marroquin et al., 2007; MacVicar & Lane, 2014). SH-SY5Y cells in 
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galactose-based culture media were generally more sensitive to H2O2 than the same cells in a 
glucose-based medium; similar amounts of cell death and Caspase-3 activation were observed at 
200 µM and 300 µM H2O2, respectively, in glucose and galactose media. This observation may 
be explained by increased reliance on oxidative phosphorylation in galactose media, but it may 
also relate to lowered intracellular oxidant defense resulting from decreased flux through the 
pentose phosphate pathway in the absence of glucose (eg. Le Goffe et al., 1999; Wu & Wei, 
2012).  
In any event, protection from H2O2-induced SH-SY5Y cell death by TPP-IOA observed 
in glucose media was not observed in galactose media. The discrepancy indicates that the 
metabolic context determines the anti-apoptotic effect of TPP-IOA. This may relate to 
differences in sensitivity to perturbed mitochondrial ATP output. If TPP-IOA sufficiently 
decreased mitochondrial ATP output, this should have a direct effect on cellular ATP levels in 
galactose-grown cells that are heavily reliant on oxidative phosphorylation. Notably, the mode of 
cell death under general lethal conditions can shift from apoptosis (which is ATP-dependent) to 
necrosis (ATP-independent) if there is insufficient cellular ATP. The lack of total cell death 
prevention (as assessed by Trypan blue exclusion counts that do not discriminate between 
apoptotic and necrotic cell death) combined with the minor, yet statistically insignificant, drop in 
the apoptotic activity marker Caspase-3 activity is consistent with such a shift in the presence of 
TPP-IOA. However, with this in mind, it is also important to note that over the concentration 
range tested, TPP-IOA did not exacerbate the amount of cell death caused by H2O2 in the 
galactose medium. This might be predicted to occur in these cells if TPP-IOA caused cellular 
ATP levels to decline to a catastrophic degree.  
 Considering that knowledge of cellular ATP levels is required in the above explanations 
for the discrepancy for TPP-IOA’s protective effect, strengthening evidence for these 
interpretations could be provided with future measurements of cellular ATP levels following 
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TPP-IOA addition to cells. Additionally, these interpretations could be further supplemented 
with measurements of glucose utilization and/or lactate production to detect changes in 
glycolytic metabolism.   
As discussed earlier, induction of mitophagy, the result of which is less cytochrome c and 
other pro-apoptotic mitochondrial proteins available for release under apoptotic conditions, could 
at least partly underlie TPP-IOA’s anti-apoptotic mechanism in cells. Notably, mitochondrial 
content markers were measured in the glucose-grown cells but not the galactose-grown cells in 
response to TPP-IOA. Therefore, it is unknown whether the same decline in apparent 
mitochondrial content had occurred in galactose-grown SH-SY5Y cells. Importantly, there is 
evidence that sensitivity to mitophagy induction is influenced by cellular dependency on 
oxidative phosphorylation. For example, cytosolic mitophagy machinery translocated to 
mitochondria in response to mitochondrial depolarization in HeLa cells when cultured in a 
glucose medium, but not when in a galactose-medium (Van Laar et al., 2011). Likewise, in 
human telomerase immortalized retinal pigment epithelial cells, uncoupling-induced mitophagy 
occurred when cultured in a glucose medium but was suppressed in a galactose medium 
(MacVicar & Lane 2014). It is thus conceivable that TPP-IOA may not have elicited the same 
mitophagy-like response in the galactose medium, where cells are more reliant on oxidative 
phosphorylation and perhaps resultantly less inclined to initiate a mitophagy response to acute 
energetic stress. With this in mind, the fact that TPP-IOA failed to protect against oxidant-
induced cell death in the galactose medium lends support to the notion that TPP-IOA’s anti-
apoptotic mechanism could involve a stimulation of mitophagy. 
Future work using various autophagy/mitophagy assays (e.g. measuring co-localization 
of mitochondria with mitophagy machinery; Klionsky et al., 2016) could provide definitive 
evidence for whether TPP-IOA is a stimulator of mitophagy. Furthermore, testing whether the 
prevention of cell death by TPP-IOA persists in the presence of mitophagy/lysosomal inhibitors 
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could provide valuable proof for whether mitophagy is a part of TPP-IOA’s anti-apoptotic 
mechanism of action in cells. Together, such findings would be yield a more complete 
understanding of TPP-IOA’s biological effects that are relevant to the molecular mechanism(s) 
through which it exerts its anti-apoptotic effect in cells. In a more general sense, the 
identification of mitophagy as part of TPP-IOA’s protective mechanism could have widespread 
implications for other mitochondrial-based therapeutics, as the functional implications of the 
previously identified disruptions to mitochondrial bioenergetics by TPP-cation based small 
molecules (e.g. Reily et al., 2013) are neither known nor been subject to experimental 
investigation. Induction of mitophagy owing to their interaction with mitochondrial energetics 
may be a fundamental effect of TPP-cation based small molecules that could at least partly 
contribute to their protective action in cells. Investigating this could be a worthwhile future goal. 
 
4.4 Potential therapeutic applications for TPP-IOA –an energetics perspective: 
 From a variety of in vitro measures at multiple levels of biological organization, this 
thesis revealed altered mitochondrial energetics in response to the anti-apoptotic molecule TPP-
IOA, and that ultimately TPP-IOA could only prevent oxidant-induced cell death of cells with 
propensity to use glycolytic metabolism rather than those reliant on oxidative phosphorylation. 
These findings imply that, in principle, relative reliance on mitochondrial energetics is an 
important cellular property that influences TPP-IOA’s anti-apoptotic efficacy in cells. These 
results offer a more nuanced understanding of TPP-IOA’s anti-apoptotic mechanism of 
protection in cells. 
A prediction from the current work is that TPP-IOA is likely to be effective in preventing 
in vivo apoptotic cell death in pathologies where, in addition to dying via the mitochondrial 
pathway of apoptosis, the major cell types affected are generally glycolytic/fermentative or 
generally less reliant on oxidative phosphorylation. Importantly, the existing data for TPP-IOA’s 
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in vivo anti-apoptotic/therapeutic utility comes from an experimental model of pathological cell 
loss (radiation exposure) in which the predominantly affected cell types are highly proliferative 
(Macià I Garau et al., 2011) and poised for glycolytic energy metabolism (Vander Heiden et al., 
2009). Thus, these previous findings do not contradict the principle outcome of the current study, 
and additionally support a testable prediction of the current work.  
Importantly, based on the current findings, TPP-IOA would be predicted to be ineffective 
in directly preventing loss of highly aerobic cells (e.g. neurons, cardiomyocytes) occurring 
through the mitochondrial pathway of apoptosis in pathological scenarios. This prediction, 
however, does not necessarily entirely rule out TPP-IOA’s utility as a therapeutic agent in 
potential pathologies of highly aerobic tissues affecting quiescent cell types that feature both a 
low regenerative capacity and highly aerobic energy metabolism, which are generally of large 
biomedical interest. A reason for this relates to possible heterogeneity of cell types and their 
potential differing metabolic properties within a highly aerobic tissue of interest. If there is an 
abundance of highly glycolytic cell types that contribute to the overall tissue pathology via death 
through the mitochondrial apoptotic pathway, then TPP-IOA’s ability to prevent such cell death 
could potentially prevent degeneration of the whole tissue.  
For example, the brain possesses a large abundance of neurons, which have high aerobic 
activity, but also features a higher abundance of astrocytes, which are less aerobically-active and 
more highly glycolytic (Belanger et al., 2011). Importantly, astrocytes serve multi-faceted 
functions in the brain, which consequently ensures proper neuronal activity (e.g. Clarke & 
Barres, 2013). Astrocyte apoptosis via the mitochondrial pathway contributes to brain pathology 
in acute neurodegenerative contexts and there is evidence that it can precede the degeneration of 
neurons (e.g. Liu et al., 1999; Takuma et al., 2004; Sofroniew & Vinters, 2010). Therefore, in 
principle, TPP-IOA could potentially afford neuroprotection in various acute brain pathologies 
by effectively suppressing apoptotic cell death of this glycolytic cell type. Aside from this brain-
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specific cell type, a more general example of a cell type suitable for protection by TPP-IOA is 
the endothelial cell. These cells are necessary for proper blood vessel functioning, which in turn 
is required for proper functioning of effector tissues (Sumpio et al., 2002). They are generally a 
highly glycolytic cell type whose apoptotic cell death is associated with acute pathologies of 
many highly aerobic tissues, including ischemia/reperfusion-like injuries (e.g. Verdegem et al., 
2014; Goveia et al., 2014; Polet & Feron et al., 2013). Inhibiting apoptosis of this cell type could 
improve survival of downstream aerobic cell types. In general, combining knowledge of cell 
type-specific metabolic properties with cell-type specific involvement in pathologies of interest 
will be essential in informing decisions to pursue potential future therapeutic applications for 
TPP-IOA. 
 
4.5 Overall Conclusions: 
 Here, investigations carried out at multiple levels of biological organization revealed 
important insights into the mitochondria-targeted anti-apoptotic molecule TPP-IOA’s 
interactions with components of mitochondrial and cellular energetics. The data indicated that 
TPP-IOA can interfere with energetic processes of both its target protein and organelle, and 
notably, in the latter was virtually unable to appreciably inhibit pro-apoptotic oxidase activity 
without concomitantly interfering with oxidative phosphorylation. Additionally, TPP-IOA’s 
protective efficacy from oxidant-induced cell death was only detectable in cultured cells with a 
propensity to use glycolytic metabolism rather than oxidative phosphorylation, indicating that 
relative cellular dependence on oxidative phosphorylation is a critical factor in allowing the anti-
apoptotic effect to be realized. Altogether, these data indicate that TPP-IOA’s interactions with 
mitochondrial energetics is likely an important factor influencing the small molecules anti-
apoptotic utility. Importantly, this information, together with knowledge of cell-type specific 
metabolic properties, can serve as a basis for rationally predicting the suitability of TPP-IOA in 
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potential future therapeutic applications. With this in mind, potential future therapeutic 
applications with TPP-IOA may be restricted to disease contexts in which either aerobic 
metabolism is reduced or highly glycolytic/less aerobic cell types are major contributors tissue 
degeneration or the general pathology.  
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Appendix I - Data: 
 
 
Figure AI.5.1: mEFP signal co-localizes with MitoTracker Red CMXRos dye signal in SH-
SY5Y cells stably expressing a gene for mitochondria-targeted mEFP, confirming 
mitochondrial localization of the mEFP.  
SH-SY5Y-mito-mEFP cells were pre-stained with MitoTracker Red CMXRos (simultaneously 
with Hoechst 33342 fluorescent dye for nuclear labelling; blue) for 30 minutes prior to imaging 
with a Zeiss Axio Observer.Z1 inverted epifluorescence microscope equipped with ApoTome.2 
optical sectioning, a 63x oil objective, and Hamamatsu camera. Images are maximum intensity 
projections of a z-stack series consisting of 25 slices, 0.25 µm apart. The image shown is of a 
single cell.  
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Figure AI.5.2: TPP-IOA alters mitochondrial network morphology in SH-SY5Y human 
neuroblastoma cells stained with MitoTracker Red CMXRos dye. 
A - D) SH-SY5Y neuroblastoma cells were pre-stained with 50 nM MitoTracker Red CMXRos 
(red signal)and Hoechst 33342 fluorescent dye (blue signal; nuclear labeling) and then imaged 
after 90 min exposure to 0.1% DMSO (B), 2 µM FCCP (C), 1 µM TPP-IOA (D), or media 
change without chemical treatment (A). Images are representative of >25 cells from two 
independent experiments for each treatment. All images were acquired using a Zeiss Axio 
Observer.Z1 inverted epifluorescence microscope equipped with ApoTome.2 optical sectioning, 
a 63x oil objective, and Hamamatsu camera, and are maximum intensity projections of z-stack 
series (≥ 25 slices, 0.25 – 0.30 µm apart).  
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Figure AI.5.3: TPP-IOA alters mitochondrial network morphology in C2C12 murine 
myoblasts. 
A, B) C2C12 mouse myoblasts were pre-stained with 50 nM MitoTracker Red CMXRos and 
imaged at 60 min exposure to 2.5 µM TPP-IOA (B) or 0.1% DMSO (A). Images are 
representative of >25 cells from two independent experiments for each treatment.  
All images were acquired using a Zeiss Axio Observer.Z1 inverted epifluorescence microscope 
equipped with ApoTome.2 optical sectioning, a 63x oil objective, and Hamamatsu camera, and 
are maximum intensity projections of z-stack series (≥ 25 slices, 0.25 – 0.30 µm apart).  
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Figure AI.5.4: TP-IOA does not prevent H2O2-induced cell death of SH-SY5Y human 
neuroblastoma cells at 5 µM and above in a glucose culture medium. 
TPP-IOA was added to culture medium simultaneously with 300 µM H2O2. Cells were harvested 
24 hours later for cell viability counts with the Trypan blue dye exclusion assay.  
Bars represent means + SEM from 3 – 5 total replicates from 2-3 independent experiments. * = 
p-value < 0.05 (one-way ANOVA with Tukey’s HSD post-hoc test). Note: Here, the counts of 
viable cells were standardized to the 300 µM H2O2 treatment group (black bar). In other 
experiments (ten total replicates from five independent experiments), 300 µM H2O2 elicited 45.6 
± 1.9 % cell loss in other experiments (see Fig. 3.11). 
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Figure AI.5.5: TP-IOA prevents H2O2-induced cell death of C2C12 myoblasts between 1 
µM and 2.5 µM but not above 5 µM in a glucose culture medium. 
TPP-IOA was added to culture medium simultaneously with 250 µM H2O2. Cells were harvested 
24 hours later for cell viability counts with the Trypan blue dye exclusion assay.  
Bars represent means + SEM from 4 – 6 total replicates from 2 -3 independent experiments. *** 
= p-value < 0.001 (one-way ANOVA with Tukey’s HSD post-hoc test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
Appendix II – Methodology - Mitochondrial Network Analysis (MiNA V1.0.0): 
Created by Andrew Valente | April 26, 2016 
The morphology of mitochondrial networks has received much attention in recent years. 
Efforts to remove subjectivity in understanding their structure and relation to biological 
processes have been made by many individuals and groups (Ahmad et al., 2013; Koopman, 
Visch, Smeitink, & Willems, 2006; Rafelski, 2013). Working off of the contributions of such 
efforts, we have here developed a plugin with the goal of making consistent, accurate 
measurements of morphological characteristics of mitochondrial networks using a single 
fluorescent image. MiNA runs in the open source program ImageJ, making easy and objective 
analysis available to researchers without the need for specific operating platforms or expensive 
software. MiNA uses existing plugins and additional processing to provide a rapid method for 
determining quantitative values that can be used as proxies in mitochondrial morphology related 
research. 
Analysis is based on prior works that make an effort to quantitatively bin features based 
on their attributes or more objectively classify features (Ahmad et al., 2013; Koopman et al., 
2006; Nikolaisen et al., 2014; Rafelski, 2013). There have been various methods of classifying 
the features. The methods used here most strongly follow the categories presented by Leonard et 
al., which uses a system of puncta, rods, networks, and large round features as the potential 
categories for classification (Leonard et al., 2015). In an effort to reduce the complexity of the 
analysis the process is simplified here to contain only 2 types of features, individuals and 
networks. 
Individuals are those which would fit the categories of puncta and rods. These features 
consist of a point or rod and do not demonstrate any sort of branching. Networks are features 
containing at least one branching point. An individual consists of only nodes and connecting 
pixels, while a network also contains branch points. This is demonstrated in Figure AII.6.1. 
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Figure AII.6.1: Demonstration of individual and network morphologies. 
 
AII.1 - Image Preprocessing Algorithm: 
AII.1.1 - Deconvolution using Estimated Blurring: 
The blurring in an image is minimally produced by the point spread function of the 
optical system. Blurring is added to an image by convolution, mathematically represented in one 
dimension as ∫f(x)g(x-τ)dτ. To remove this effect the opposite must be done, which is a 
deconvolution. Here, the function convolved with the real unblurred image is the point spread 
function. We estimate the PSF using the Diffraction PSF 3D plugin and the excitation 
wavelength of the dye used. The NA is set to ½ the NA of the objective (this was found to give 
good results through testing). NA or numerical aperture is a measure of the range of angles that 
the optics can accept light from. This is used as a guess for how blurred the image is and used for 
deconvolution using the DeconvolutionJ plugin. The plugin used employs an iterative Wiener 
filtering method to deconvoluted the image. A Wiener filter is not a typical kernel convolution, 
but a statistical estimate of how the signal appears without the addition of noise from the 
instrument and environment. This filter is iterated until the mean squared error between random 
processes and signal are minimized. The deconvoluted image’s pixel dimensions are recalibrated 
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afterwards. This is to ensure the physical size of the image is not removed by the processing. The 
effects of this estimated deconvolution method are shown in Figure AII.6.2. 
 
Figure AII.6.2: Effects of deconvolution to image. Blurring kernel shown in bottom left. 
 
AII.1.2 - Contrast Limited Adaptive Histogram Equalization: 
The images produced by deconvolution are often dimmed. They may also demonstrate 
regions of greater brightness than others. To improve the contrast between all features and the 
background CLAHE is used. The process aims to equalize the histogram about the image 
without exaggerating features too aggressively. CLAHE is demonstrated on the previously 
deconvoluted image and shown in Figure AII.6.3. 
 
Figure AII.6.3: Effects of CLAHE on image. 
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AII.1.3 – Removal of Spurious Contrast by Median Filtering: 
Using a 2-pixel radius, a median filter is applied to the image. This filter replaces the 
central pixel of the image with the median of the surrounding pixels in a 2-pixel radius. This aids 
in ensuring spurious details such as salt and pepper noise are removed and not counted as 
individuals by the program. This filtering method’s effect is demonstrated in Figure AII.6.4. 
 
Figure AII.6.4: Median filtered image to reduce noise and spurious points. 
 
AII.2 – Image Analysis Algorithm: 
Now, the goal becomes to extract the number of features, classify them as individual or 
networked and make measurements as to how long individual features are. This is done by 
converting the image into a skeleton, which is only one pixel wide. To do this requires a number 
of steps outlined here. 
AII.2.1 - Thresholding and Conversion to Binary: 
The image is first step is to produce a threshold image using ImageJ’s default algorithm. 
The default pics the threshold value by first removing outliers from the histogram, then 
iteratively smoothing the histogram with a 4 element averaging window until only 2 peaks exist. 
The midrange between these is the threshold value. Pixels with values greater than this are set to 
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a maximum, and those below it to a minimum. This is then converted to a binary image. This 
makes mitochondrial signal 1 and everywhere else 0. The result is shown in Figure AII.6.5. 
 
Figure AII.6.5: Binary Image produced by thresholding with default algorithm. 
 
AII.2.2 - Skeletonizing the Binary Image: 
A skeleton is then produced of the binary image using the Skeletonize 3D plugin. This 
iteratively removes external pixels until everything is represented by lines 1 pixel in width. The 
skeleton is shown overlaying the original image in Figure AII.6.6. 
 
Figure AII.6.6: Skeleton overlayed on top of the binary image. 
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AII.3 - Limitations: 
Currently there are some limitations to the software. It can only handle two-dimensional 
information effectively. The three-dimensional skeletons typically fail due to poor resolution in 
the Z plane causing discontinuities. This may be corrected using interpolation, but has not been 
implemented here. It is also important to note that the skeletons produced are not perfect. They 
are an approximation and errors do occur. It is important to look at the overlaid skeleton and 
determine whether or not the fit is deemed accurate enough for analysis purposes. 
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